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Vaccination is one of the greatest achievements in biomedical research pre-
venting death and morbidity in many infectious diseases through the induc-
tion of pathogen-specific humoral and cellular immune responses.
Currently, no effective vaccines are available for pathogens with a highly
variable antigenic load, such as the human immunodeficiency virus or to
induce cellular T-cell immunity in the fight against cancer. The recent
SARS-CoV-2 outbreak has reinforced the relevance of designing smart
therapeutic vaccine modalities to ensure public health. Indeed, academic
and private companies have ongoing joint efforts to develop novel vaccine
prototypes for this virus. Many pathogens are covered by a dense glycan-
coat, which form an attractive target for vaccine development. Moreover,
many tumor types are characterized by altered glycosylation profiles that
are known as “tumor-associated carbohydrate antigens”. Unfortunately,
glycans do not provoke a vigorous immune response and generally serve as
T-cell-independent antigens, not eliciting protective immunoglobulin G
responses nor inducing immunological memory. A close and continuous
crosstalk between glycochemists and glycoimmunologists is essential for the
successful development of efficient immune modulators. It is clear that this
is a key point for the discovery of novel approaches, which could signifi-
cantly improve our understanding of the immune system. In this review,
we discuss the latest advancements in development of vaccines against gly-
can epitopes to gain selective immune responses and to provide an over-
view on the role of different immunogenic constructs in improving
glycovaccine efficacy.
Introduction
Cellular glycosylation is a highly regulated multistep
process that is present in all life forms, although it
greatly differs across the different taxa [1,2]. In mam-
malian cells, glycans can be attached to proteins and
lipids on the cell surface, but also in the cytoplasm or
even the nucleus. Whereas viruses generally hijack the
glycosylation machinery of host cells, many bacterial
species, fungi, and parasites carry their own set of gly-
cosylation enzymes that enable to decorate their sur-
face with glycans. Indeed, bacteria are covered by a
dense glycan-coat exposed to their outer surface or as
a polysaccharide capsule and some species even con-
tain proper glycosylated glycoproteins. These patho-
genic glycans have proven to be attractive targets for
vaccine development.
In the last 20 years, advancements on the development
of efficient methodologies and highly sensitive analytical
tools for studying the glycome have increased our knowl-
edge on profiling the variability of glycan structures and
on determining their key role(s). In addition, a synergistic
interplay between immunologists and chemists has
enabled the development of novel approaches, which
have significantly improved our understanding of the
immune system. There is a growing body of literature
focused on the development of a wide range of glycan-
based chemical tools able to modulate the immune
response, and there is increased understanding of key
mechanisms that orchestrate the biological role of gly-
cans in immunity [3–8]. In this regard, a large pool of
structurally well-defined glycan derivatives including nat-
ural glyco-epitopes, glyco-analogues, and glycomimetics
has become available due to advancements in chemical
and chemoenzymatic protocols for their synthesis [9–12].
Moreover, these structures have been assembled into syn-
thetic and semisynthetic glycoconjugates containing
selected mono- and multivalent carriers that also play a
key role in the type of immune response induced through
the activation of specific immune compartments [13–19].
Manipulation of the immune system always carries an
intrinsic risk, and therefore, a close and continuous cross-
talk between glycochemists and glycoimmunologists is
essential for the successful development of efficient
immune modulators.
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The intent of this review is to highlight some recent
and most relevant advances in the field of synthetic
glycobiology that enable the modulation of immune
responses (Fig. 1).
Starting from an immunological point of view, we
have selected those reports that stand out among the
major contributions to the field over the last 10 years,
with particular attention to those studies that provide
powerful examples of the utility of synthetic glyco-
epitope-based vaccine prototypes. We specifically dis-
cuss chemical tools that enable the modulation of
immune responses in cancer and in some relevant bac-
terial and viral infections. In general, sample cases
have been selected to provide an overview of the dif-
ferent immunological effects according to the use of
different carriers, the diversity of pathological epitopes
targeted, and the mode of their presentation to the
immune system. The main and most recent efforts to
circumvent the poor immunogenicity of glycan epi-
topes through the use of specific immunogenic carriers
are also included.
Immunologists perspective: the need
for molecular approaches
Effective, specific, and safe regulation of the immune
response using various approaches (i.e., vaccines, phar-
macological agents, or biological drugs) represents the
holy grail of contemporary immunotherapy [20]. From
an immunologist’s point of view, a great number of
potential ways to manipulate immune reactivity in a
positive or negative manner exist, making the immuno-
logical network a medicinal chemist’s playground.
However, the sensitivity of such grand design requires
an in-depth knowledge of the immune system not only
to recognize potential drug targets, but also to predict
the influence of manipulating single or multiple targets
on the overall immunological balance and immune
homeostasis.
Perhaps the most challenging task of our immune
system is not to efficiently eliminate invading patho-
gens or to remain tolerant to self-antigens, but to
maintain a steady and lifelong balance between the
two. Since both immune reactivity and tolerance are
fought on the same “battlefield,” any therapeutic mod-
ulation of an immune response has the potential to
disrupt this balance in the opposite direction. This
may result in either an excessive inflammatory reaction
or exaggerated immune suppression and lead to, for
example, autoimmune or chronic inflammatory dis-
eases or increased susceptibility to infection.
Targeting the innate immune responses
In evolutionary terms, innate immunity precedes adap-
tive immunity and while lacking antigen-specific recog-
nition, it can respond quickly and eradicate pathogens
even before systemic infection [21]. It works by recog-
nizing pathogen- and danger-associated molecular pat-
terns via a group of sensors called pattern recognition
Fig. 1. Glycoconjugate vaccines for the
modulation of innate and adaptive immune
responses toward different pathogens and
cancer. Conjugation of glycan epitopes
(represented here by general N-glycan as an
example of an oligosaccharide structures) to
suitable carriers ranging from proteins,
peptides, oligonucleotides, dendrimers,
liposomes, and glycolipids, to ZPS and,
more recently, NPs, represents the main
strategy currently being exploited for
development of vaccines against pathogens
and tumors. They have been developed to
ensure the proper activation of specific
parts of the immune system, such as
effector B/T cells, NK cells, macrophages,
and in general APCs.
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receptors (PRRs). These are classified into various
receptor families, most important being Toll-like recep-
tors (TLRs), nucleotide-binding oligomerization
domain-like receptors, retinoic acid-inducible gene I-
like receptors, and C-type lectin receptors (CLRs)
[22,23]. The activation of these receptors by various
conserved molecular determinants present on microbes
and viruses culminates in an effective immune
response, tailored in such a way to most efficiently
remove the invading pathogen. The central role of
PRRs in innate immune activation makes them the
perfect target for immunomodulatory drugs, and sev-
eral natural PRR ligands can be successfully imitated
by small- to medium-sized synthetic molecules with
agonistic activity (i.e., able to bind and activate a
receptor) or antagonistic activity (i.e., blockers of the
agonist action) [24–27]. In terms of vaccine develop-
ment, effective PRR agonists can serve a very impor-
tant role as adjuvants [28,29]. The induction of
optimal antigen-specific and memory immune
responses is the primary goal of vaccination. Although
these responses are carried out by cells of the adaptive
immune system (T cells and B cells), their initiation
and level of quality are determined already at the
innate level. Both macrophages and B cells can serve
the antigen-presenting function. However, it is the den-
dritic cell (DC) that is the superior professional
antigen-presenting cell (APC). This is due to the DC’s
unique and outstanding capacity to sample and present
antigen, as well as their efficient detection of patho-
gens via expression of the above mentioned PRRs [30].
Chemical entities designed as PRR agonists can there-
fore serve as important immunomodulatory tools.
However, particular emphasis should be given on the
type of immune response they could elicit in the long
term. Indeed, the immune system may also attack self-
tissues. Thus, a deeper understanding of the cellular
players, receptors, and mechanisms associated with the
complex events related to the immune response is
required to avoid undesired aggressive immunity to
self-antigens.
Overcoming the poor immunogenicity of glycan
epitopes
The last two decades have witnessed a significant
amount of discoveries on the immunogenic role, and,
in general, the biological role of glycan epitopes in
pathological settings [31–34]. These findings have
prompted glycoscientists to investigate the glycan
mimicry approach to develop new efficient therapeutics
for pathological conditions, such as cancer and infec-
tions. Specifically, different approaches have been
investigated including the development of
carbohydrate-based vaccines, glycan-based targeting of
APCs, immune checkpoint inhibitors, and direct modi-
fiers of cellular glycosylation [8,31,35–39].
Due to their T-cell independency, glycans are unable
to induce the production of long-lived protective anti-
bodies and do not establish immunological memory,
especially in young children and the elderly population
[40]. Glycans can be recognized by B cells and are
intracellularly processed; however, they mainly trigger
the secretion of low-avidity antibodies [immunoglobu-
lin M (IgM)] [41]. Indeed, human blood contains many
of these natural low-affinity IgM antibodies that rec-
ognize carbohydrate epitopes (e.g., A, B, and H anti-
gens in blood groups) [42]. The unique exception of
this behavior is related to zwitterionic polysaccharides
(ZPS) expressed at the surface of some Gram-positive
and Gram-negative bacteria [43]. Therefore, the main
strategy exploited for vaccine development consists of
the conjugation of glycan epitopes to proper carriers
(Fig. 1) ranging from proteins, to peptides, oligonu-
cleotides, lipids, ZPS, and, more recently, nanoparti-
cles (NPs) [44–48], in order to ensure the proper
activation of specific arms of the immune system.
Specifically, proteins have been used as immuno-
genic carriers to trigger adaptive responses [antibody
(Ab) production] against the carbohydrates conjugated
to them, and in parallel, carbohydrates have been con-
jugated to proteins to modulate the immune responses
against the protein itself [45,49].
In addition, lipids and lipidated derivatives, lipid A,
lipoarabinomannan (LAM), monophosphorylated
derivatives of lipopolysaccharides (LPS), the palmitoy-
lated Pam3CSK4, ZPS, and cytosine-phosphate-
guanosine (CpG) oligodeoxynucleotides (ODNs) have
shown significant immunostimulatory activity as TLR
agonists [4]. As an example, the most conserved lipid A
portion of the LPS stimulates host innate immune cell
responses through recognition by TLR4 or binding to
the cytoplasmic inflammasome via caspases [50,51].
Since activation of TLR4 signaling controls and potenti-
ates both innate and adaptive immune responses, pre-
clinical and clinical studies have demonstrated that
TLR4 agonists [52] can be used as immune-adjuvants
for vaccine formulations aimed at fighting infection and
cancer [53]. Therefore, manipulation of LPS-induced
immune signaling pathways by means of synthetic or
natural TLR agonists is intensively studied as a source
of immune-adjuvants for vaccine formulations.
CpG ODNs are short, single-stranded DNA oligo-
mers with unmethylated cytosine-phosphate-guanine
(CpG) oligodeoxynucleotide motifs, whose sequences
are derived from bacterial DNA and are not frequent
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in mammalian DNA [54,55]. The adjuvant effect of
coadministered CpG-ODN is well established also in
the field of carbohydrate vaccines. Indeed, CpG-ODNs
are able to elicit an efficient defensive immune
response in mammals through the TLR9 receptor
pathway raising a strong innate immune response,
which is a prerequisite to elicit robust cellular and
humoral adaptive responses against coadministered
antigens [56]. Accordingly, CpG immunostimulatory
sequences have been shown to act as potent adjuvants
of type 1 immune responses, demonstrating their
promising role both as adjuvants in vaccine formula-
tions and as carrier molecules for the development of
synthetic and self-adjuvating conjugate vaccines [57].
Within this framework, nanotechnology has been
widely exploited with the aim to improve immune
responses in either cancer or infectious diseases.
Metal-based NPs, virus-like particles (VLPs), and lipo-
somes are the most investigated nanotools employed in
vaccine development. Nanotechnology approaches
have been proposed to improve the efficacy of
carbohydrate-based vaccines by means of the enhanced
DC targeting and/or the enhanced delivery of
immunomodulators to program DCs. In addition, NPs
improve antigen stability and allow co-delivery of
adjuvants/immunogenic carriers and other molecules
of interest on the same nanoplatform [58,59].
Glycoconjugate vaccines for the
activation of immune response in
infection and cancer
Vaccines are one of the greatest revolutions in medical
sciences in the 20th century, saving millions of lives.
We expect that in the next few years, vaccination will
be applied to tackle unmet medical needs, such as in
infectious diseases still waiting for an effective treat-
ment and for the prevention of microbial infections
caused by antibiotic-resistant microorganisms. More-
over, novel vaccines that boost immune responses in
cancer could significantly aid existing immunothera-
peutic approaches to elicit tumor eradication and to
prevent tumor recurrence and metastasis. The rele-
vance of this therapeutic approach has become partic-
ularly urgent due to the current public health
emergency related to the COVID-19 pandemic. Indeed,
the development of a specific and effective anti-SARS-
CoV-2 vaccine has become a highly demanding and
urgent effort to manage the spread of COVID-19 and
to reduce mortality.
Glycoconjugate vaccines are among the safest and
most efficacious vaccines developed so far to prevent
antibiotic-resistant microbial infections. They represent
one of the keys for success of vaccination in children,
as demonstrated by the dramatic reduction in infec-
tions from Streptococcus pneumoniae, Haemophilus in-
fluenzae type b, and Neisseria meningitidis.
Improving the immunogenicity of pathogen
glycan structures through glycoconjugate
vaccines
Several technologies have been developed to generate
glycoconjugate vaccines, leading to constructs with dif-
ferent molecular architecture and properties. The cur-
rently licensed glycoconjugate vaccines are based on
the chemical manipulation of isolated saccharide anti-
gens or their fragments obtained by controlled hydro-
lytic depolymerization of the native polysaccharide,
followed by random conjugation to carrier proteins
such as diphtheria toxoid [DT; at its nontoxic mutant
cross-reacting material 197 (CRM197)] and tetanus
toxoid (TT). Although these vaccines are able to
induce protective immunity in the host; however, they
are characterized by heterogeneous cross-linked struc-
tures raising significant hurdles on batch consistencies
during the manufacturing process and making the
identification of structure–immunogenicity relation-
ships a challenging task. Modern approaches in the
rational design of glycoconjugate vaccines take into
account a number of variables, such as the saccharide
chain length, the carbohydrate-protein ratio, the nat-
ure of the linker, and the conjugation methods or plat-
form [44,45,60]. Accordingly, the most recent strategies
consider the use of pure and chemically well-defined
carbohydrate antigens generated by means of cutting-
edge synthetic methodologies or enzymatic approaches
that are covalently linked to immunogenic carrier pro-
teins or peptides using site-selective conjugation che-
mistries. In this section, we will discuss some recent
advances in the field of antibacterial glycoconjugate
vaccines according with the immunogenic carrier
included in the conjugates. In addition, we report on
the state of the art related to vaccine development for
human immunodeficiency virus (HIV). HIV has been
selected as an example of viral pathogens, because in
the last decade the possibility to exploit glycans for




Bacteria are covered by a multilayered and complex
structure referred to as the cell envelope (Fig. 2),
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highly impermeable and essential for viability. This cell
envelope has attracted considerable interest as a poten-
tial target of novel potential vaccine formulations. In
Gram-negative bacteria, the presence of the additional
barrier afforded by the outer membrane (OM) pro-
vides an extra layer of protection.
The OM [61] encases the peptidoglycan (PGN)
layer, and together, they form a highly hydrophobic
and sophisticated asymmetric lipid bilayer barrier that
enhances resistance and protection from antibiotics
and host immune mechanisms. LPS are the main com-
ponent of the OM, and they play a crucial role in bac-
terial growth and survival (Fig. 2). They are complex
glycoconjugates with a common structural motif con-
sisting of a hydrophilic heteropolysaccharide cova-
lently linked to the lipophilic moiety, known as lipid
A. The heteropolysaccharide consists of a core
oligosaccharide and an O-specific polysaccharide, also
named O-chain or O-antigen. The lipid A anchors
these macromolecules to the membrane. An additional
carbohydrate-based coat embedding and protecting the
bacteria is the capsular polysaccharide (CPS), which is
also used by bacteria in immune evasion mechanisms
[62,63]. Both LPS and CPS greatly contribute to the
structural integrity, protection, and bacterial survival
and play a key role in mediating host–bacterium inter-
actions, like colonization, adhesion, tolerance for com-
mensal bacteria, and symbiosis. Furthermore, they
often represent highly conserved factors, mediating
immune recognition and virulence. Thus, they are
attractive candidate antigens, which can be exploited
either in vaccine development or in diagnostics.
Indeed, several studies have identified lipopolysaccha-
ride and CPSs as potential vaccines candidates [64–67],
and several of them are already in use in the clinics
(Tables 1 and 2) [40].
In this regard, the use of protein–polysaccharide
conjugates has so far been the most investigated
approach to prepare antibacterial vaccines, and this
will be addressed in Protein-based glycoconjugates sec-
tion, describing the main strategies reported to date in
the field of protein-carbohydrate conjugates (i.e., use
of mimics/analogues, bioengineering methods, site-
specific/random protein conjugation). Next, some sam-
ple cases related to the use of different immunogenic
carriers (i.e., oligonucleotides and lipids as TLR
ligands, section Oligodeoxynucleotide- and lipid-based
glycoconjugates: targeting of TLRs) and of multivalent
nanoconstructs (section Nanoglycoconjugates) will be
briefly discussed. Linker/Spacer used in some of
the glycoconjugate vaccines described in the follow-
ing sections (Protein-based glycoconjugates,
Oligodeoxynucleotide- and lipid-based glycoconjugates:
targeting of TLRs and Nanoglycoconjugates) has been
reported in Table 2 together with the related conjuga-
tion strategies employed for their preparation.
Protein-based glycoconjugates
The concept of conjugate vaccines (e.g., glycans cova-
lently linked to immunogenic proteins) was studied by
Avery [68] in 1931 and has been introduced in the 90s
in the field of antibacterial vaccines [69]. The main rea-
son of their outstanding success is that the immune
system of young children (below 2 years of age), as
well as the immune system of the elderly (above
60 years) and of immunocompromised people, is
unable to develop long-lived antibodies against plain
bacterial polysaccharides [70]. Indeed, polysaccharides
are T-cell-independent antigens and they are not able
to trigger the secretion of antibodies capable of confer-
ring long-term protection of the host (immunological
memory). This is apparently due to the inability of
polysaccharides to be properly presented to T cells.
The seminal finding that pneumococcal antigens recog-
nized by the immune system is polysaccharides [71],
inspired, almost 100 years ago [68], the hapten-carrier
conjugation strategy (where the hapten is any small
molecule able to trigger immune responses only when
covalently linked to an immunogenic carrier). This
approach overcame the poor immunogenicity of CPS
by their covalent conjugation to immunogenic protein
carriers. In this way, B cells can recognize the polysac-
charides via their B-cell receptor and thanks to the
carrier the processed fragments from the protein–
polysaccharide conjugate can be loaded on major his-
tocompatibility complex (MHC)-II prompting the help
of T cells (Fig. 3) [49,72,73].
Once this tri-component synapse (digested or pro-
cessed antigen [72], MHC-II, and T-cell receptor) is
established, the T-helper cell can provide B cells with
the stimulatory and cytokine-mediated signals to pro-
duce and secrete high-affinity antibodies [immunoglob-
ulin G (IgG)]. Thanks to this mechanism, B cells can
also differentiate into memory B cells, a fundamental
pool of cells that guarantees immunological memory.
Fig. 2. Gram-positive and Gram-negative cell envelope and structure of the main cell wall components. Figure reprinted from Ref. [333].
Copyright 2018, Springer Nature.
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Table 1. List of glycoconjugate vaccines licensed for use in the USA. OMP, outer membrane protein complex of the B11 strain of












Sharp & Dohme Corp
(Kenilworth, NJ, USA)
















































































ahttps://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states; bFor Hib (Haemophilus influenzae type b), the
table does not include multivalent formulations active also toward other diseases.
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Table 2. Saccharide antigens, carrier, linker/spacer of some of the glycoconjugate vaccine described in this manuscript.
Saccharide antigen Carrier Linker/spacer
Conjugation
method Ref
PRP (Pedvav-Hib/Merck) Neisseria meningitidis outer
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Table 2. (Continued).
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Recent studies proposed an alternative mechanism
governing the immune response to a glycoconjugate
vaccine. According to this hypothesis, not only peptide
but also glycopeptide fragments resulting from the gly-
coconjugate processing are exposed to the T-cell recep-
tor in the context of MHC-II, raising specific T-cell
clones referred to as Tcarb [72,74]. Regardless of the
specific mechanism, one of the main properties of gly-
coconjugate vaccines is their ability to induce immuno-
logical memory against polysaccharides, which cannot
be reached using pure polysaccharide vaccines (irre-
spective of the age of administration) [40]. Glycoconju-
gate vaccines represent one of the major breakthrough
of modern medicine and opened a new era in the field
of vaccinology preventing infectious diseases affecting
infants and young children, both in industrialized and
developing countries. This research area has been thor-
oughly discussed over the last few years in many excel-
lent and more focused reviews. Consequently, in
the following paragraph, besides a brief description of
the general features of the immune response to
carbohydrates and protein glycoconjugates, only a
selection of the most relevant and innovative strategies
emerged in the field during the last decade are high-
lighted and critically discussed. For a systematic and
updated analysis of the state of the art of this key
research area, the readers are referred to more compre-
hensive accounts in recent literature [8,39,40,44,45,
47,60,75–78].
Currently, licensed glycoconjugate vaccines, such as
those targeting S. pneumoniae, N. meningitidis, H. in-
fluenzae type b, and Salmonella typhi, were obtained
through isolation of the polysaccharide from the
pathogen and subsequent random conjugation to car-
rier proteins exploiting the amino acid residues that
are exposed on the surface of the protein (Tables 1
and 2) [79,80]. Up to date, five carrier proteins have
been used for all licensed conjugate vaccines (TT; DT;
CRM197; nontypeable H. influenzae protein D;
OMPC, the outer membrane protein complex of
meningococcus B). In addition, other proteins, such as
the recombinant Pseudomonas aeruginosa exotoxin A
Fig. 3. Schematic representation of the proposed mechanism of T-cell activation by glycoconjugate vaccines. In general, unconjugated
polysaccharides only evoke short-term Ab responses, mainly of the IgM type, which does not result in long-lasting B-cell memory
responses. Coupling of polysaccharides to protein carriers, switches the immune reaction from T-cell-independent to a T-cell-dependent
response, now culminating in a high-affinity Ab response and long-term B-cell memory. Steps related to antigen processing and
presentation of glycoconjugate vaccines which result in helper CD4+ T-cell induction of B-cell production of IgG mAbs against the
polysaccharide have been depicted. Figure reproduced from Ref. [72].
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(rEPA), have been employed at preclinical and clinical
levels [81]. One successful story using the glycoconju-
gate approach is the case of S. pneumoniae, a Gram-
positive bacterium with more than 90 known serotypes
(i.e., more than 90 structurally different CPS known to
coat each bacterial serotype). Streptococcus pneumo-
niae CPS is key molecules for bacterial survival and
infection, and they are attractive epitopes for vaccina-
tion [82]. The introduction of pneumococcal conjugate
vaccines, which consist of a mixture of glycoconjugates
based on the CPS of 10 and 13 different serotypes (in-
dependently conjugated to immunogenic protein carri-
ers), has reduced the incidence of pneumococcal
disease caused by the serotypes contained in the vac-
cines. Notwithstanding the success of these vaccines,
several major challenges remain mostly due to the need
for higher Ab titers to remove the bacterial carriage
from the upper respiratory tract of the host more effi-
ciently [83]. To solve these challenges, nanotechnology
has been used to design and prepare new vaccination
approaches against S. pneumoniae as discussed below.
Glycoconjugate vaccines prepared by following clas-
sical random conjugation routes result in heteroge-
neous mixtures of high molecular weight, cross-linked,
and rather undefined constructs. Consequently, their
physicochemical characterization and the maintenance
of the batchwise consistency are challenging tasks,
which represent crucial issues for licensing authorities.
In addition, the immunogenicity of the final conjugates
is strongly influenced by several interconnected charac-
teristics, such as the acetylation pattern of the sugar,
saccharide length, saccharide/protein ratio, conjugation
chemistry, and type of linker eventually used for cou-
pling. All these variables have to be taken into account
in vaccine design and were sometimes shown to signifi-
cantly affect the immunological outcome of the glyco-
conjugate construct [8,45,60,84–86]. Glycoconjugates
based on chemically well-defined structures, selected
by rational design, can confer more reproducible bio-
logical outcomes and better safety profile. Therefore,
this approach has emerged at the forefront of vaccine
development. The first commercialized synthetic vac-
cine, Quimi-Hib* (1, Fig. 4, Table 2), a H. influenzae
type b vaccine, developed in Cuba, is an outstanding
example of the reliability of this approach. It consisted
of a synthetic CPS antigen (polyribosylribitol phos-
phate, PRP) conjugated to thiolated TT through a 3-
(maleimido)propanamide linker (Fig. 4, Table 2) [87–
90]. This pioneering work demonstrated the feasibility
of large-scale synthesis of carbohydrate antigens, the
pharmaceutical development of a synthetic conjugate-
vaccine. In this regard, in order to assess the minimal
PRP protecting repeating unit, an extensive synthetic
work has been recently done by Seeberger and
coworkers [91]. Immunological data in Zika rabbit
model allowed the identification of the tetrameric
immunogenic epitope 2 (Fig. 4, Table 2). In this
framework, semisynthetic glycoconjugate vaccines have
entered different phases of clinical trials in the last few
years. Furthermore, glycoconjugate vaccines composed
of LPS (or detoxified LPS) covalently linked to carrier
proteins and/or gold NPs (AuNPs) are currently being
evaluated in mice and nonhuman primates with
promising results regarding their immunogenicity and
protective efficacy [92,93].
Thus, the combination of technologies to obtain
more defined carbohydrate antigens with higher pur-
ity and novel approaches for protein modification
(protein engineering) for regio- and chemoselective
ligation are key points [45]. Despite the fact that to
date, the expression of biosynthetic pathways and gly-
coengineering to produce bacterial glycans provides
cheaper and versatile method to develop carbohy-
drates vaccines [94], recent advances in carbohydrate
synthesis allowed access to many complex oligosac-
charides on a large scale and with precise control of
the structure [44]. Synthetic strategies aimed at the
development of conjugate vaccines containing pro-
tein/peptide carriers are mainly based on the incorpo-
ration of either a synthetic bacterial carbohydrate
antigen [95–105], their synthetic structural mimics, or
chimeric oligosaccharides [11]. Relevant examples of
the latter approach were reported during the last dec-
ade. Neisseria meningitidis is a Gram-negative encap-
sulated bacterium and a major cause worldwide of
bacterial meningitis occurring beyond the neonatal
period. Among the thirteen serotypes of N. meningi-
tidis, group A (MenA) is the main serotype responsi-
ble for epidemic meningococcal disease in developing
countries [106,107]. MenA CPS, made up of (1 ? 6)-
linked 2-acetamido-2-deoxy-a-D-mannopyranosyl
phosphate repeating units variably O-acetylated at 3-
and 4-OH, exhibits poor hydrolytic stability due to
the lability of the anomeric phosphodiester linkage.
Although currently licensed antimeningococcal glyco-
conjugate vaccines contributed to a decrease in dis-
ease incidence [108], the availability of shelf-stable
fully liquid formulations based on protein conjugates
of MenA CPS mimics is very attractive for the devel-
opment of an improved and more efficient anti-MenA
vaccine [109]. To this end, short chain carbocyclic
analogues of MenA CPS (where the pyranose ring
oxygen of N-acetyl-D-mannosamine is replaced with
a methylene group) [110] have been synthesized [111],
chemically conjugated to CRM197 carrier protein (3a–
c; Fig. 4, Table 2) and immunologically evaluated in
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mice. The conjugated carbocyclic-trimer 3c elicited
specific anti-MenA polysaccharide antibodies with
in vitro bactericidal activity [112]. Very recently, the
synthesis of longer chain carbocyclic analogues was
accomplished. In particular, the hexamer and the
octamer were protein-conjugated (3d–e; Fig. 4,
Table 2) and immunologically evaluated, showing
that conjugate 3e is capable of binding anti-MenA
CPS antibodies and it is able to induce an immune
response against the non-O-acetylated MenA CPS.
Most importantly, random chemical 3/4-O-
acetylation of the carbocyclic octamer followed by
conjugation to CRM197 provided a new glycoconju-
gate able to strongly inhibit the binding of a MenA-
specific bactericidal monoclonal Ab (mAb) and poly-
clonal serum to the CPS. In addition, the latter con-
jugate raised high titers of anti-MenA CPS antibodies
with bactericidal activity comparable to the currently
licensed MenA vaccine [113]. This study represents
the first proof of concept that glycomimetics can be
used to simulate natural saccharide antigens for the
development of effective conjugate vaccines with
improved stability.
A semisynthetic vaccine candidate against
Shigella flexneri 2a, the pathogen responsible for ende-
mic shigellosis among children in developing countries,
was developed by Mulard et al. In particular, glyco-
conjugate 4 (Fig. 4, Table 2) consisting of a trimer of
the pentasaccharide epitope of S. flexneri 2a conju-
gated to TT protein was able to induce a long-lasting
protective immune response [95]. Notably, conjugate 4
has completed the first in human phase 1 study very
recently [114].
In addition, the use of synthetic and/or semisyn-
thetic carbohydrate antigens allows the site-specific
introduction in the polysaccharide of structurally dif-
ferent linkers containing chemical groups (e.g.,
hydrazines, maleimides, azides, alkynes) suitable for
site-selective conjugation to the side chain of amino
acid residues on the protein carrier [45,115]. This
Fig. 4. Structures of glycoconjugate vaccine containing carrier proteins: 1 commercially available Haemophilus influenzae type b vaccine
(QuimiHib); [87] 2 synthetic glycoconjugate containing the CPS antigen (PRP) of H. influenzae type b; [91] 3 synthetic glycoconjugates
containing carbocyclic analogues of MenA CPS; 4 synthetic glycoconjugates containing the repeating unit of the O-antigen of
Shigella flexneri [95]. The carbohydrate epitopes are reported in black and the linker/spacer in green.
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represents one of the most used approaches for site-
selective coupling of carbohydrate epitopes with the
carrier protein. For example, lysine, aspartic acid, and
glutamic acid are the most targeted amino acid resi-
dues for either random or site-selective conjugation in
some licensed glycoconjugate vaccines. The targeting
of highly nucleophilic cysteines either naturally occur-
ring or genetically installed at the protein surface is
another employed approach. Indeed, thiols can react
rapidly with a wide range of sugar derivatives
appended with electrophilic functional groups [116].
Tyrosine residues are less abundant (and usually less
exposed) than lysine, and hence, they are optimal tar-
gets for site-selective glycoconjugation [117]. Glycan
linkage to preactivated tyrosines enables addressing
the conjugation to a few predetermined sites, generat-
ing more defined conjugates presenting multiples pro-
tein copies along the carbohydrate chain. An example
of the use of tyrosine ligation is the site-selective con-
jugation of the CPSs from Group B Streptococcus
(GBS) types II and V, a pathogen responsible for
neonatal infections, by strain promoted azide-alkyne
cycloaddition to the more exposed tyrosine residues of
the pathogen-related proteins GBS80 and GBS67
[118]. The immunogenicity of the tyrosine-directed
GBS type II polysaccharide-GBS80 and GBS type V
polysaccharide-GBS67 conjugates was comparable to
the corresponding CRM197 conjugates randomly func-
tionalized with the carbohydrate epitopes [119,120]. In
addition, the GBSII-GBS80 conjugate elicited distinct
murine Ab clones able to recognize either the GBSII
polysaccharide and the GBS80 protein epitopes
(Table 2). These findings opened the way to a new
kind of glycoconjugates, where homologous proteins
are used with a dual role as carrier and antigen [60].
Other approaches which have been developing in the
last decade are based on selective modification of natu-
ral amino acids (mainly lysine, aspartic, and glutamic
acid residues) and on the introduction of unnatural
(i.e., not naturally found or encoded) amino acids. For
example, enzymes can react with specific residues incor-
porated in a short amino acid tag, which was previously
introduced either in the protein or in the sugar epitope
[121]. Conjugation of large polysaccharides to one
specific amino acid residue has been achieved by micro-
bial transglutaminase-catalyzed lysine modification
[122]. In addition, cysteines occurring as disulfide
bridges can be regioselectively targeted by reductive
cleavage followed by stapling of the resulting cysteine
residues with an electrophilic agent [122]. The most
exploited strategy to obtain proteins with specific tags is
via protein engineering with unnatural amino acids,
which can be incorporated through a modified
translational machinery, mainly in Escherichia coli uti-
lized as the expression system. This methodology com-
bined with the wide variety of unnatural amino acids
currently available can significantly expand the tools for
protein conjugation, and it is being used for instance by
the Sutrovax company. Their “XtractCF” system was
developed to produce proteins displaying unnatural
amino acids, which can be further conjugated to saccha-
ride antigens by means of click chemistry. This method
is currently being applied for the development of an
antipneumococcal conjugate vaccine [123].
Recently, the protein glycan coupling technology
was successfully employed in the design of novel glyco-
conjugate vaccines [124]. In this approach, both the
saccharide antigen and the carrier protein are
expressed in E. coli and coupled in vivo [47]. Indeed,
the N-linked glycosylation system from Campylobac-
ter jejuni can be functionally expressed in E. coli to
synthesize the heterologous polysaccharides on its gly-
cosyl carrier lipid [125]. Glycoconjugate production in
E. coli requires a genome cluster encoding the bacterial
polysaccharide, a plasmid encoding the carrier protein,
and the oligosaccharyltransferase PglB from C. jejuni,
whereby the PglB transfers the resulting lipid-linked
oligosaccharide to the target carrier protein containing
the specific consensus acceptor sequence.
Glycoengineering was initially used by the Glycov-
axyn company (now LimmaTech Biologicals, Sch-
lieren, Switzerland) to produce several structurally
different glycoproteins. They biosynthesized different
bacterial saccharides, ranging from O-antigens of
Gram-negative bacteria (Salmonella enterica, Shigella
spp, and E. coli LPS) to CPS (Staphylococcus aureus
serotype 5 and 8 and S. pneumoniae). The correspond-
ing protein conjugates were prepared mostly using
detoxified exoprotein A from P. aeruginosa (rEPA) as
a carrier. In some cases, the homologous S. aureus a
toxin Hla was conjugated to the CPS of the same bac-
terium [126]. Notably, the availability of additional
oligosaccharyltransferases (such as PglL and PglS)
expands the pool of tools available for protein glyco-
engineering [127,128]. Many glycoconjugate vaccines
produced by protein glycan coupling technology have
entered clinical trials over the past few years. Phase 1
clinical trials have successfully been completed for
monovalent vaccines against Shigella dysenteriae type
1 and S. flexneri 2a infections, and a tetravalent anti-
extraintestinal E. coli (ExPEC) vaccine is progressing
to Phase 2 studies [114,129,130]. Overall, this platform
provides fast access to glycoconjugates targeting many
important pathogens against which no licensed vacci-
nes are available, and also to improve the production
of several vaccines already on the market.
14 The FEBS Journal (2021) ª 2021 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
Glycoconjugate vaccines in infections and cancer M. Anderluh et al.
Oligodeoxynucleotide- and lipid-based
glycoconjugates: targeting of TLRs
Despite that the conjugation to immunogenic proteins
has been the most widely investigated approach in the
design of antibacterial glycoconjugate vaccines, some
success stories, including the use of other immunogenic
carriers, have been reported. Of note, CpG-ODN was
used as an external adjuvant to increase the antibacte-
rial immunity against S. pneumoniae polysaccharide
types 19F and 6B induced by polysaccharide-protein
conjugates [131]. Furthermore, in glycoconjugate vacci-
nes based on bacterium-related carrier proteins the
adjuvant activity of CpG was beneficial to enhance the
anticarrier protein immune response. Indeed, the co-
administration of CpG with an anti-H. influenzae type
b (Hib) polysaccharide conjugate vaccine in mice was
able to increase the amount of neutralizing antibodies
against both the polysaccharide and the Hib-related
protein component of the vaccine that are generally
induced at low levels [132]. On the other hand, to the
best of our knowledge, despite the potential of syn-
thetic vaccines using TLR agonists like CpG motifs as
build-in adjuvant [133], there are no examples on the
design and synthesis of a multicomponent antibacterial
vaccine based on carbohydrates conjugated to CpG.
Conjugates containing the monophosphorylated
derivative of N. meningitidis lipid A (MPLA) were also
investigated as vaccine prototypes for bacterial infec-
tions [134]. As an alternative to the traditional protein
conjugate vaccines, the bacterial antigen a-(2 ? 9)-
polysialic acid, the CPS of serotype C of N. meningi-
tidis, has been taken as a model to study the immuno-
genicity of MPLA conjugates. Glycoconjugates 5a–d
(Fig. 5, Table 2) were prepared using synthetic a-
(2 ? 9)-linked di-, tri-, tetra-, and pentasialic acids,
which were conjugated to MPLA [134]. These MPLA
glycoconjugates were administered to mice as liposo-
mal formulations and elicited robust immune
responses comparable to those induced by the tradi-
tional protein glycoconjugates (including adjuvant). In
particular, the trimer 5b and the tetramer 5c elicited
the highest immune responses that mediated effective
killing of group C N. meningitidis cells. This study sup-
ports the hypothesis of the self-adjuvating properties
of MPLA conjugates. In addition, a recent study on a
synthetic glycoconjugate with potential antituberculosis
vaccine activity shed new light on the immunostimu-
lant and adjuvant activity associated with MPLA car-
rier [135]. The glycoconjugate 6 (Fig. 5, Table 2)
consisting of the tetrasaccharide of mycobacterial
LAM conjugated to the primary position of the glu-
cosamine residue of MPLA induced a robust IgG Ab
response in mice [135]. Notably, the structure of the
linker and the conjugation site of the carbohydrate
antigen epitope on MLPA appeared to play a key role
in the immunogenicity.
Nanoglycoconjugates
Notwithstanding the efficacy of protein–polysaccharide
conjugate vaccines, several major challenges still
remain to be addressed. As previously mentioned,
there is a need for higher Ab titers to more efficiently
remove the bacterial carriage in the upper respiratory
tract of the host [83]. Nanotechnology has been
employed in the design of new vaccination approaches,
and glyco-liposomes have been proposed as viable
alternative to the covalent conjugation of a peptide or
protein to the bacterial saccharide antigens [136]. The
pioneering work of Mulard et al. [137] is an outstand-
ing example of the power of this approach. In particu-
lar, fully synthetic liposomes were functionalized at
their surface with two sets of S. flexneri 2a synthetic
pentasaccharides (as B-cell epitopes, mimicking the O-
antigen of S. flexneri), and the universal T-helper epi-
tope derived from influenza virus HA 307–319. These
synthetic liposomes were shown to effectively elicit Ab
responses against the native lipopolysaccharide in vivo
[137–139]. In case of S. pneumoniae, the tetrasaccha-
ride repeating unit of the CPS of S. pneumoniae sero-
type 14 was conjugated to diacylthioglycerol. The
conjugate was subsequently employed to prepare
peptide-free glyco-liposomes. A synthetic a-GalCer
analogue named PBS57, which can be presented by
APCs via the MHC-I-like CD1 molecules to invariant
natural killer T (iNKT) cells, was also included. Vacci-
nation studies established that this nanosystem was
able to induce high IgG titers, giving a response
against S. pneumoniae serotype 14 superior to that of
commercially available Prevnar13 (Table 1), the clini-
cally employed conjugate vaccine, which contains the
CPS conjugates of 13 S. pneumoniae serotypes. More-
over, the formulation into liposomes compared with a
simple mixture of the target tetrasaccharide and the
iNKT cell adjuvant was relevant for obtaining the
immunological response.
More recently, a specific liposomal design has been
developed to address full S. pneumoniae serotype pro-
tection with a single vaccine formulation [140]. This
innovation is based on the colocalization of noncova-
lently linked complementary antigens into a liposome
formulation. More specifically, twenty different CPSs
from S. pneumoniae were encapsulated into liposomes
and the vesicle surfaces were coated with immunogenic
proteins, such as CRM197, an a-glycerophosphate
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oxidase (GlpO), and a bacteriocin ABC transporter
transmembrane protein (PncO). The encapsulated lipo-
somes displaying CRM197 showed high efficacy in
inducing Ab titers and protection comparable to Pre-
vnar 13 and Pneumovax 23 (Table 1), the currently
clinically employed pneumococcal vaccines. The vac-
cine nano-platforms with functionalized GlpO and
PncO demonstrated an immunogenicity comparable to
the commercial PCV13 available vaccines, while simul-
taneously safeguarding against virulence transition of
niche-replacement serotypes. A second generation of
polysaccharide-encapsulated liposomes was recently
introduced, which provides protection against 24
strains. These liposomes were generated through an
alternative streptavidin-biotin linkage and by removing
the GlpO protein antigen and increasing the amount
of PncO antigens [141].
Carbohydrate-coated AuNPs have also been studied
in vivo as a carrier for synthetic S. pneumoniae carbo-
hydrate antigens. Specifically, a synthetic repeating
unit of the antigenic CPS from S. pneumoniae serotype
14 was loaded onto 2 nm AuNPs in the presence of
the OVA323–339 peptide as the MHC-II restricted pep-
tide [142]. The simultaneous presence of the S. pneu-
moniae serotype 14 synthetic fragment and the OVA
peptide on the AuNPs was crucial to trigger specific
Fig. 5. Structures of: 5 synthetic glycoconjugates containing the repeating unit of CPS of serotype C of Neisseria meningitidis; [142] 6
synthetic glycoconjugate containing the tetrasaccharide of mycobacterial LAM; [134,135] 7 synthetic glyco-nanoconstruct containing
carbohydrate epitopes of CPS from serotype 14 and serotype 19F of Streptococcus pneumoniae [143]. The carbohydrate epitopes are
reported in black, the immunogenic carriers in blue, the linker/spacer in green.
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IgG against S. pneumoniae serotype 14 in vivo. In
addition, the degree of loading of the synthetic carbo-
hydrate fragments onto the AuNPs significantly
affected the Ab titer outcome, demonstrating a loading
threshold (approximately 20% of the overall ligand
density) below which the ability to trigger high IgG
titers in mice was drastically compromised. Recently,
two (minimal) carbohydrate epitopes from two differ-
ent S. pneumoniae capsules (serotype 14 and serotype
19F) were both loaded on the same AuNPs. A
T-helper peptide was also included leading to the
heterogeneous construct 7 (Fig. 5, Table 2) [143]. Sur-
prisingly, specific IgG titers against serotype 14 were
enhanced by the copresence of the serotype 19F frag-
ment on the same AuNPs. Conversely, no immunolog-
ical response against serotype 14 and serotype 19F was
obtained when AuNPs were separately loaded with the
single epitopes and coadministered. The independent
conjugation of synthetic S. pneumoniae serotype 3 and
14 CPS fragments on bacteriophage Qb VLPs via a
copper-catalyzed click reaction has also been described
(Table 2). These functionalized VLPs were able to trig-
ger specific IgG serotypes in mice, protecting against
S. pneumoniae [144].
Final remarks and future perspectives
At present, vaccines represent one of the top product
categories among the biologic medicines in clinical use
or under development, and within them, glycoconju-
gate vaccines are key and serve a prominent role. As a
consequence, there is a strong demand of new glyco-
conjugate vaccines, with enhanced safety and efficacy,
and capable of eliciting a more robust immune
response to tackle unmet medical needs or to amelio-
rate currently licensed vaccine constructs. To this end,
methods simplifying and accelerating the preparation
and manufacture of glycoconjugates have emerged
over the past decade. Among them, the control of site
specificity in protein conjugation holds great promise.
Glycoconjugate vaccine prototypes obtained by site-
selective conjugation demonstrated outstanding
immunological activity even with few, short but well-
defined oligosaccharide antigens, allowing to establish
more precise structure–immunogenicity relationships
which will help to understand the antigen presentation
mechanisms.
Supported by cutting-edge synthetic methodologies,
in particular by automated solid-phase oligosaccharide
synthesis, new and promising strategies and techniques
have emerged during the last years to reach such an
ambitious goal: produce new, safe, well-defined and
highly protective glycoconjugate vaccines, easier to
characterize in their physicochemical properties in
order to facilitate their manufacture process, and their
introduction on the market with affordable costs. In
this regard, a variety of chemical and enzymatic liga-
tion techniques provide multiple options for research-
ers to design specific glycoconjugate vaccines. In
addition, complementary strategies such as chemoenzy-
matic protocols (which include glycoprotein remodel-
ing, like the protein glycoengineering techniques
mentioned above) and nanotechnology-based
approaches are among the most promising prospects
for the development of glycoconjugate vaccines cap-
able of providing increasingly broad coverage and pro-
tection from deadly infectious diseases.
Human immunodeficiency virus
The clustered high-mannose patch as an antigenic
epitope
Even after 40 years of attempts, an effective vaccine
against the HIV is still not available [145]. A late-stage
clinical trial (NCT02315703) is going to start with the
“mosaic” HIV-1 vaccine candidate [146] based on
priming with adenovirus serotype 26 (Ad26) vectors,
which encode for the Env/Gag/Pol antigens, and
boosting with Ad26 in the presence of aluminum-
adjuvanted clade C Env gp140 protein. From a carbo-
hydrate point of view, it is widely accepted that gly-
cans play a key role in the immunology and pathology
of HIV. In the accompanying review (“emerging glyco-
based strategies to steer immune responses”), we dis-
cussed how certain carbohydrates are able to target
APCs and can thus be used as vectors to bring other
synthetic antigens to APCs for further T-cell activa-
tion. Nevertheless, carbohydrate-dependent epitopes
on glycoprotein gp120 exist, and thus, selected HIV
glycans might be used for the generation of functional
IgGs.
In this section, we present an overview of the differ-
ent strategies, which have been proposed to elicit anti-
bodies capable of neutralizing the virus, taking into
account the specific N-linked glycans on gp120. Then,
linker/spacer used in the glycoconjugate vaccine proto-
types and conjugation strategies has been described in
Table 3.
In some cases, N-linked glycans on gp120 are
directly involved and required for the binding of
broadly neutralizing antibodies (bNAbs) isolated from
patients, while in other cases they contribute to the
display of the protein epitope, or to the conforma-
tional stability of the HIV envelope (Env) trimer.
These strategies include the development of synthetic
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glycopeptides (section Protein/peptide-based glycocon-
jugates) through the identification of the minimal neu-
tralizing epitopes recognized by bNAbs, the mimicking
of the clustered glycan presentation by means of
nanotechnology-based scaffolds (section Nanoglyco-
conjugates), and the use of bacterial lipooligosaccha-
ride (LOS) fragments (section Nanoglycoconjugates).
The glycosylation of the HIV envelope spike has
been recognized as a big challenge and an opportunity
at the same time. Indeed, in up to 20% of infected
individuals bNAbs have been found [147], and many
of these antibodies ( 40%) target a dense high-
mannose region on gp120 [148], known as the “high-
mannose patch” (HMP; Fig. 6). These antibodies neu-
tralize diverse strains of HIV, and they are often pro-
tective in animal models of infection, thus providing
clues for vaccine design. In addition, the unusual clus-
tering of glycans, and in particular of the high-
mannose type oligosaccharides of the HMP, results in
a significant opportunity from an immunological
perspective. Indeed, the HMP has been identified as a
nonself-element, which could be exploited to elicit a
specific immune response against the virus [149]. Many
attempts to develop glycoconjugate vaccines struc-
turally mimicking the HMP and thus following the
principle of epitope-focused vaccine design have been
performed with the aim of eliciting bNAbs targeting
this conserved epitope [150]. For example, the PG9,
PG16, and CH01–CH04 antibodies recognize a glycan-
dependent region within the first and second variable
loops (V1/V2) of gp120 [151,152]. Crystal structure
studies of the complex between PG9 and a scaffolded
V1V2 domain revealed that the Ab makes contacts
with two high-mannose glycans at the Asn160 and
Asn156 sites and a contiguous V1V2 peptide b-strand
[153]. Other bNAbs, such as PGT121–123 and PG125–
128, target the third variable (V3) loop domain of
gp120 [154,155]. The V3 domain of HIV-1 typically
contains three potential N-glycosylation sites with the
N295 and N332 sites at the base and the N301 site
Fig. 6. High-mannose structures found in HIV gp120. Adapted from [334].
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within the loop [156], and these domains are recog-
nized by bNAbs. In Fig. 7, the trimeric HIV-1 envel-
ope including the membrane proximal external region
(MPER) in gp41 on the viral spike is depicted with the
different bNAbs (including the glycan specific ones)
that target the different regions in the HIV-1 envelope
trimer. Altogether, these findings provide the rationale
to generate anticarbohydrate vaccines for HIV or to
use these antibodies as therapeutic agents in passive
immunization [157,158].
Protein/peptide-based glycoconjugates
A lot of effort has been focused on the identification
of the minimal neutralizing epitope recognized by
bNAbs in order to facilitate the design of the proper
HIV immunogens. Early synthetic efforts in the field
were focused on the design of N-glycopeptides derived
from the V3 domain. The chemoenzymatic synthesis of
a disulfide-linked, cyclic V3 glycopeptide containing
the N-linked core pentasaccharide (Man3GlcNAc2) at
two conserved sites (Asn332, Asn295), with improved
resistance to proteolysis in comparison with the naked
peptide, has been reported [159]. The synthetic V3 gly-
copeptides carrying a high-mannose N-glycan at
Asn332 could indeed mimic the conserved epitope rec-
ognized by several bNAbs and elicited glycan-
dependent Ab responses in immunization studies in
animals. In follow-up experiments, a synthetic self-
adjuvating three-component immunogen, consisting of
a 33-mer V3 glycopeptide epitope, a universal T-helper
epitope P30, and a lipopeptide-based TLR-2 ligand
(Pam3CSK4), elicited substantial glycan-dependent
antibodies with a broader recognition of HIV-1 gp120
compared with the nonglycosylated V3 peptide
(Table 3). These findings suggested that the self-
adjuvating synthetic glycopeptide can serve as an
important component to elicit glycan-specific antibod-
ies in HIV vaccine design [160]. Moreover, the highly
conserved N-glycans at Asn332 are at the center of the
intrinsic HMP. Nevertheless, about 17% of HIV iso-
lates carry the Asn332 to Asn334 mutation [161]. In
this regard, synthetic V3 glycopeptides from HIV-1
A244 gp120 carrying an Asn334 high-mannose glycan
displayed the proper recognition by bNAbs PGT128
and PGT126. Subsequent, rabbit immunization with
synthetic A244 glycopeptides elicited substantial
glycan-dependent antibodies with broad reactivity
toward various HIV-1 gp120/gp140 carrying Asn332
or Asn334 glycosylation sites [162].
In contrast, strong binding of V1V2 bNAbs required
both oligomannose derivatization and conformational
stabilization by disulfide-linked dimer formation of syn-
thetic V1V2 peptides [163]. In an effort to dissect the
glycan-binding specificity of the bNAbs PG9 and PG16,
a library of different V1V2 cyclic glycopeptides derived
from the HIV-1 strains CAP45 and ZM109 was synthe-
sized by Wong et al. [164]. Specific high-mannose and/or
complex-type glycans were installed chemoenzymatically
at three predetermined N-glycosylation sites (Asn160,
Asn156, and Asn173). Whereas Man5GlcNAc2 at
Asn160 was critical for recognition, an additional sialy-
lated complex-type N-glycan at the secondary glycosyla-
tion site facilitated the enhanced binding affinity. Similar
results were obtained by probing a glycan array, which
demonstrated that particularly PG16 was able to bind
complex-type multi-antennary N-glycans bearing a termi-
nal a-2,6-linked sialic acid unit [165].
Another strategy to design carbohydrate vaccines
against HIV is based on mimicking the high-mannose
type oligosaccharides of the HIV envelope (Env) glyco-
protein using different scaffolds in order to display
these glycans in a multivalent fashion [166,167]. As a
first step, a series of gp120 V1V2 N-glycopeptides,
bearing well-defined N-glycans at Asn160 and Asn156,
and derived from the CRF 01AE A244 HIV-1 strain
were designed and chemically synthesized [168]. The
corresponding peptide sequence consisted of 35 amino
acids of the main region of the envelope glycoprotein
recognized by the PG9 Ab, while the carbohydrate
domain targeted two Man5GlcNAc2 residues, encom-
passing the binding epitope of PG9. Additionally,
other simplified glycopeptides were pursued with
Man3GlcNAc2 and chitobiose (GlcNAc2) units to
probe the relevance of the outer mannose residues for
bNAb recognition. Following a classic glycoconjugate
vaccine approach, conserved oligomannose
Fig. 7. Epitope specificity of known bNAbs to HIV-1 envelope.
Figure reproduced from Refs. [335,336].
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Man9GlcNAc2 clusters have also been tetravalently
displayed on a galactose scaffold and chemoselectively
conjugated either to thiolated keyhole limpet hemo-
cyanin (KLH; Fig. 8B, Table 3) or to a thiolated T-
helper peptide from TT [169].
Subcutaneous immunization of rabbits resulted in
antisera with high titers of IgG antibodies. However,
most of the IgGs were directed against the linker
rather than the carbohydrate antigens, indicating that
the choice of the linker has a key role in vaccine
design. Indeed, the antisera were unable to neutralize
the virus even if a slight reactivity toward HIV-1
gp120 was detected. These data confirmed that only
low levels of specific anticarbohydrate and neutraliz-
ing antibodies were raised. Similar results were
obtained with divalent Man9GlcNAc2 displayed on a
cyclic peptide scaffold, which was conjugated to an
outer membrane protein complex carrier (Fig. 8A
Table 3). Again, specific HIV neutralization was not
observed in immunization experiments in both guinea
pigs and rhesus macaques [170]. In an effort to use
minimal glycan epitopes, the tetramannoside Man4,
corresponding to the D1 arm of Man9GlcNAc2, was
chosen as the antigen fragment and conjugated to
BSA [171]. Multivalent BSA-(Man4)14 was indeed
immunogenic and elicited Man-specific IgG, which,
however, did not cross-react with gp120 (Fig. 8C,
Table 3).
Several efforts were aimed at pushing the chemical
design toward either a better control on the
Fig. 8. Multivalent high-mannose glycan
clusters. Specifically: (A) Cyclic peptide
bearing two Man9GlcNAc2 glycans,
conjugated to outer membrane protein
complex (OMPC) of Neisseria meningitidis.
(B) Tetravalent Man9GlcNAc2 conjugated
through a flexible linker to KLH protein. (C)
Man4 tetrasaccharide conjugated to BSA
protein. (D) Heteromultivalent clustering of
Man8 or Man9 on Qb phage particles. (E)
PAMAM8-Man9 dendrimers conjugated to
CRM-197 protein. (F) Highly multivalent
Man9 dendrimers. Figure reproduced from
Ref. [166]. Copyright 2014, Springer Nature.
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oligomannoside display and a higher glycans density
on the scaffold in order to mimic the heavy glycosyla-
tion of HIV Env. Unfortunately, all these attempts did
not lead to anticarbohydrate antibodies able to cross-
react with HIV Env. This is the case of rabbits immu-
nized either with VLPs (icosahedral capsids of bacte-
riophage Qb) [172] functionalized with Man4 and
Man9 (Fig. 8D, Table 3) or with the synthetic 4-valent
and 8-valent Man4 and Man9 dendrons based on
polyamidoamine (PAMAM) scaffold further conju-
gated to the immunogenic carrier protein CRM197
(Fig. 8E,F, Table 3) [173]. One of the main reasons
for the failure of the systems described above has been
attributed to the oligomannoside display in (semi)syn-
thetic nanoclusters, which also includes the flexibility
of the antigenic presentation and the distance between
the targeted glycans on the scaffold/carrier (Table 3)
[174]. A warning on high-mannose oligosaccharide dis-
play in synthetic constructs has been raised by a recent
study that demonstrates that endogenous mannosidase
trimming favors the elicitation of antibodies targeted
to the glycan core instead of Mana1–2Man-specific
antibodies [174]. All these examples also indicate the
difficulty in rationalizing the results due to the differ-
ent protocols employed for the immunization (e.g.,
adjuvants, animal models, carrier proteins or immuno-
genic peptides, amount of antigens in primary immu-
nization, and boosts).
Nanoglycoconjugates
Nanotechnology has also been explored for the design
of vaccine candidates against HIV. Studies, based on a
“minimalistic” or “reductionist” approach, included
the use of nanoscaffolds, optimal presentation of mini-
mal epitope moieties, and the use of immunogenic
fragments instead of whole carrier proteins. Especially,
AuNPs have been widely investigated as carriers for a
fully synthetic carbohydrate vaccine candidate. In a
preliminary study, AuNPs coated with Man4 at 10%
and 50% NP-coating densities were able to inhibit the
gp120/2G12 binding (Table 3) [175]. Next, the same
group tailored these AuNPs with a TT immunogenic
peptide and included Man5, in addition to Man4, to
get a better mimic of the gp120 glycan display. In par-
ticular, NPs in the range <100 nm able to reach the
lymph nodes were used [175]. However, immunization
of rabbits only elicited carbohydrate-specific IgGs,
which were not able to recognize gp120 (M. Marradi
and F. Chiodo, personal communication).
Another strategy was based on a bacterial LOS frag-
ment from the Rhizobium radiobacter Rv3 strain. The
selected LOS fragment contains a Mana1–2Mana1–
2Mana1–3Man-oligomannose epitope that resembles
the HIV Env oligomannosides (Table 3). Indeed,
immunization of mice with heat-killed bacteria elicited
HIV-1 gp120 cross-reactive antibodies. Thus, a syn-
thetic LOS-based heptasaccharide was conjugated to
BSA, which elicited low titers of bNAbs in human- Ab
transgenic rats [176]. In an effort to generalize this
approach, these synthetically modified bacterial oligo-
mannoside mimetics are now used to probe 2G12
recognition [177].
In general, two main points need to be clarified:
(a) how the antigen display on NPs affects the
immunological outcome; and, (b) how the NPs behave
in vivo. Concerning the latter, functionalized NPs both
have to reach the lymph nodes and to enter the B-cell
zone where the follicular DCs initiate the efficient
crosstalk with B cells for specific and functional Ab
production. Recently, a study on glycan-engineered
NPs shed light on this issue [178]. A gp120-derived
mini-protein (engineered outer domain of gp120) and
a large gp140 Env trimer were used as “reductionist”
antigens. Multivalent antigen presentation onto the
NP and the presence of high-mannose oligosaccharides
were essential for mannose binding lectin (MBL)-
mediated innate immune recognition. This in turn was
critical for efficient humoral responses, presumably by
promoting a complement-dependent antigen transfer
to follicular DCs in vivo. Indeed, experiments with
MBL-deficient mice or deglycosylated immunogens
lowered Ab production, which matched with a loss of
follicular DC colocalization. Thus, glyco-engineered
NPs with a selected array of synthetic glycans can
enhance recognition by MBL, the transfer of antigen
to the B-cell compartment and the overall humoral
immune response. Next, this concept was translated to
different-sized polystyrene (PS) NPs, which were func-
tionalized with a synthetic trimannoside. While 40 nm
PS NPs accumulated in follicular DCs, > 100 nm PS
NPs did not reach the follicles with detrimental effects
on the B-cell response.
AuNPs have also been used as scaffolds to host
high-mannose type oligosaccharides as targeting moi-
eties to improve DC uptake, antigen presentation, and
T-cell crosstalk in order to modulate innate immunity
and to enhance the humoral immune response against
the selected HIV-1 peptides [179]. NP-based codelivery
of the HIV-1 antigen SLYNTVATL (HIV Gag p17
peptide) and a dimannose (Mana1–2Man) derivative
improved the capacity of DCs to process and present
HIV-1-peptides to autologous T cells from HIV-1
patients. Moreover, compared to HIV peptides alone,
an increased HIV-specific CD4+ and CD8+ T-cell pro-
liferation and a higher pro-TH1 and pro-TH2 cytokine
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and chemokine secretion, along with other proinflam-
matory cytokines [tumor necrosis factor-a and inter-
leukin (IL)-1b], were recorded. The induction of HIV-
specific cellular immune responses is a good prerequi-
site to activate B cells and to enhance the humoral
response. More information on targeting DCs through
AuNPs, not strictly related to glycan functionalization,
can be found elsewhere [180]. In general, the uptake of
AuNPs by immune cells usually triggers the produc-
tion of proinflammatory cytokines, and, for this rea-
son, AuNPs are considered as “immunostimulatory”
[181]. Much emphasis has been put on the size and
shape of the AuNPs core, although general conclu-
sions are sometimes difficult to draw, as the NP coat-
ing also plays a key role, especially when recognition
elements as glycans are present in the organic shell.
Recombinant HIV-1 gp120/gp41 Env glycoprotein
trimers have been designed as stable structural mimet-
ics of the native virion-associated spike with the aim
of overcoming the limitations of immunizing with
gp120 monomers [182]. These stabilized trimers effi-
ciently present multiple bNAb epitopes and elicit
bNAbs against the autologous tier 2 (typically resis-
tant) viruses. The rationale behind this strategy is
based on experiences with the hepatitis B virus [183]
and human papillomavirus [184], in which protective
antiviral subunit vaccines have been achieved by pre-
senting the viral surface immunogenic protein on
VLPs. This VLP multivalent approach profits of some
key characteristics, namely: (a) the size, which resem-
bles that of native viruses, (b) the multiple copies of
the antigen in a limited region of space which results
in high local concentration, and (c) the flexibility of
the carrier controlling B-cell activation (a rigid carrier
should trigger stronger activation signals than a more
flexible one). In this sense, synthetic liposomes of
around 100 nm were used to display well-ordered HIV
Env spike trimers in high-density arrays (Fig. 9) [185].
This synthetic nanoconstruct with 300–500 spikes/lipo-
some enhanced the specific activation of B cells
through B-cell receptor engagement compared with
soluble trimers, as demonstrated by an ex vivo experi-
ment using B cells from b12 knock-in mice, for exam-
ple, transgenic knock-in mice expressing, in the
physiological immunoglobulin heavy and light chain
loci, two well-studied bNAbs, 4E10 and b12 [186].
Furthermore, the trimer-conjugated single bilayer lipo-
somes enhanced the generation of germinal center B
cells in vivo, indicating that the secondary lymphoid
organs were efficiently reached and that the activated
B cells underwent IgG class switching. Moreover, neu-
tralizing antibodies were elicited in immunized rabbits,
although at low levels, using the trimer-conjugated
liposomes in the presence of the exogenous adjuvant
Adjuplex [185].
Final remarks
Overall, the examples reported above confirm the dual
function of HIV glycans: (a) as targets for bNAb pro-
duction against the clustered HIV carbohydrates and
(b) as targeting moieties toward an enhanced antigen
presentation by DCs, able to activate T-cell-mediated
immune responses. The influence of NP engineering in
glycoconjugate vaccines in relation to the transport
mechanisms in vivo has been the object of a recent
Fig. 9. Structural view of the HIV Trimers. (A) EM micrographs of JRFL gp140-foldon oligomers, JRFL NFL, and JRFL SOSIP trimers. Scale
bars, 20 nm. Representative trimers are circled in red. Top and aside views of representative trimer is depicted below the EM micrographs.
(B) Schematic representation of liposomes displaying HIV-1 trimers. Figure reproduced from Ref. [185].
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commentary [187], which links the critical issues of
nanoparticle glycosylation, antigen display, and size to
other systems, such as polysaccharide- and outer mem-
brane vesicles-based vaccines.
Improving the antitumor immunity through
glycoconjugate vaccines
Toward the development of therapeutic glycoconjugate
vaccines based on tumor-associated carbohydrate
antigens
Anticancer vaccines are based on different grounds
compared with the antimicrobial vaccines described in
section Improving the immunogenicity of pathogen
glycan structures through glycoconjugate vaccines, as
they are developed for therapeutic purposes instead of
preventive goals. The difficulty in developing prophy-
lactic anticancer vaccines is mainly due to the fact that
cancer cells are considered by the immune system as
“self-” elements and do not induce high inflammatory
signals (unlike viruses and bacteria). Moreover, thera-
peutic vaccines are often based on targeting
overexpressed tumor antigens that, however, often
occur at relatively late stages of tumor progression.
The aberrant expression of glycans on both cell surface
glycoproteins and glycolipids, either in terms of
amount of glycans and the presence of truncated
forms, has been considered a fingerprint of several
cancer cell phenotypes [38,188,189]. The expression of
these glycans epitopes, commonly referred to as
tumor-associated carbohydrate antigens (TACAs;
Figs 10 and 11), has been associated with tumor pro-
gression and aggressiveness, as well as to modulation
of immune recognition and evasion in cancer [190]. In
addition, the role of TACAs in the maintenance of
stemness, tumor development, and metastasis of cancer
stem cells has been recently reviewed [191].
Tumor-associated carbohydrate antigens are
regarded as a promising anticancer epitopes and thus
have been considered as target molecules for anti-
cancer carbohydrate-based vaccines [8,12,31,36–
39,188,192–195]. As in the case of HIV (section
Human immunodeficiency virus), carbohydrates are
therefore treated as antigens toward which specific and
efficient IgG responses might be generated. Many
Fig. 10. Schematic representation of potential strategies for the display of TACAs onto multivalent scaffolds (including viruses, VLPs,
polymer conjugates, liposomes, and NPs) and for the activation of specific antitumor adaptive immune responses.
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Fig. 11. Overview of the most representative TACAs expressed on glycoproteins and glycolipids on the cancer cell surface.
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investigations have indeed resulted in TACA-specific
antibodies able to target the tumor, for either diagnos-
tic or therapeutic purposes. Some of these antibodies
have been through preclinical and early-stage clinical
testing against some cancer types (e.g., unituxin, dinu-
tuximab) [196]. Nevertheless, TACAs commonly show
weak immunogenicity (T-cell-independent type II anti-
gens) and they have low in vivo stability/availability
[36,188]. To overcome these issues glycoconjugate vac-
cines employing structurally diverse immunogenic car-
riers, glycomimetics, TACA analogs, and metabolic
oligosaccharide engineered (MOE) vaccines have been
developed [8,197]. Here, we report on some of the
main recent advancements in the development of
TACA-based therapeutic vaccines in cancer. In partic-
ular, we will discuss the outcome of some fully syn-
thetic vaccine prototypes, emphasizing the role of: (a)
the selected carrier (sections Glycoconjugate vaccines
containing mucin-like antigens: the role of the
immunogenic carrier and of multivalent antigen dis-
play and Nanoglycoconjugates); (b) multivalent pre-
sentation of the antigen (sections Glycoconjugate
vaccines containing mucin-like antigens: the role of the
immunogenic carrier and of multivalent antigen dis-
play and Nanoglycoconjugates) and (c) of glycomimet-
ics (section Glycomimetics in the discovery of
anticancer glycoconjugate vaccines) on the immunolog-
ical outcome In addition, mucin-like antigens will be
discussed in more detail according to the huge pro-
gress, made in this field (section Glycoconjugate vacci-
nes containing mucin-like antigens: the role of the
immunogenic carrier and of multivalent antigen dis-
play). In Fig. 11, the structure of the most representa-
tive TACAs expressed on glycoproteins and glycolipids
on cancer cells surface is depicted.











(c) Lewis antigens, including: Galb1–4[Fuca1–3]GlcNAc-
R (Lewis X, Lex), Fuca1–2Galb1–4[Fuca1–3]GlcNAc-R
(Lewis Y, Ley), NeuAca2–3Galb1–4[Fuca1–3]GlcNAc-R
(sialyl Lewis X, sLex), NeuAca2–3Galb1–4[Fuca1–4]
GlcNAc-R (sialyl Lewis a, sLea); (d) Truncated mucin-
type O-glycan epitopes including: GalNAca-Ser/Thr
(Thomsen-nouveau, Tn antigen), Galb1–3GalNAca-Ser/
Thr (ThomsenFriedenreich, TF or T antigen),
NeuAca2–6GalNAca-Ser/Thr (sialyl-Tn, sTn) and
NeuAca2–6Galb1–3GalNAca-Ser/Thr and NeuAca2–
3Galb1–3GalNAca-Ser/Thr (sialyl-TF, sTF, including 2–
3-sialyl-TF and 2–6-sialyl-TF); (e) tetra-antennary
N‑linked glycans, and an increase in the a2–8‑linked poly-
mer known as polysialic acid [189,198–210].
Several pioneering studies [211–214] have paved the
way for the development of glycoconjugate vaccines
containing glycan epitopes. Significant contributions
have been made during the last three decades, and
some TACA-based conjugates have entered clinical tri-
als, but only some of them have reached randomized
Phase III trials for melanoma, breast cancer, and non-
small-cell lung cancer (among others theratope, OPT-
822, GM2-KLH, racotumomab, and GD2-directed
mAb) [38,188,215–218]. Although significant advance-
ments have been made in the field of TACA-based
vaccine development, several issues have so far pre-
vented the carbohydrate-protein conjugate vaccines
from getting FDA approval. The main concerns of
vaccine researchers are related to the choice of the
proper carrier protein, the undesired cross-reactivity
against the carrier protein and the linker employed for
the conjugation, the low yield of the conjugation reac-
tion, the hydrolytic stability of the glycan conjugate,
and, finally, the targeting of specific immune compart-
ments. Moreover, difficulties in isolating particular gly-
can epitopes from natural sources have limited vaccine
design and development for a long time. Advance-
ments in synthetic carbohydrate chemistry and the
availability of high performance spectroscopic tech-
niques have allowed to address some of these issues in
the last two decades and to access a wide range of
complex glycans, which can now be used in conjuga-
tion and immunization protocols [219–222].
The classical carrier proteins (e.g., BSA, KLH, DT,
OVA, TT, CRM197) have been widely employed in the
development of TACA-based glycoconjugate vaccines;
however, different carrier proteins resulted in different
immune outcomes, as was shown for ganglioside-
protein conjugates. Several cancers are characterized
by the overexpression of some particular gangliosides
(Fig. 12) [205,214,223]. The biological effects associ-
ated with overexpression of gangliosides are not fully
clarified and still under investigation; however, some
seminal studies [214,223] employed these glycan epi-
topes for the development of TACA-based vaccines.
Immunization studies in mice using GD3 conjugated
to different carrier proteins demonstrated that the
strongest Ab titers were obtained with the GD3-KLH
conjugate compared with other carrier protein conju-
gates [211]. Similar results have been reported about
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Fig. 12. Structures of: 8 unimolecular pentavalent vaccine containing MUC antigens together with the Globo-H, and GM2 ganglioside
[222,242,243]; 9 TACA-MUC1 glycopeptide conjugated with TT as a carrier protein [248], 10 which contains four copies of Tn antigen, a Th
epitope, a CTL epitope, and a TLR2 ligand were combined in a glycoconjugate construct [253]; 11 MUC1-TF and sTn glycopeptides
conjugated to Qb [255]; TACA antigens conjugated to PS A1 (12) and PS B (13) [257]. Qb conjugate image is reproduced from Ref. [255].
Copyright 2019 American Chemical Society.
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conjugates containing mucin-like antigens (Fig. 11)
[212]. In contrast, the fully synthetic glycosphingolipid
Globo-H epitope (Fig. 12) conjugated to CRM197 pro-
tein was more efficient in eliciting IgG Ab production
compared with KLH conjugates, and these antibodies
cross-reacted with Globo-H and Globo-H-related epi-
topes (e.g., SSEA3 and SSEA4) [221]. The commonly
known CA19-9 or sLea marker is expressed on glycol-
ipids or glycoproteins on the cell surface of several
human cancer types. Vaccination studies using a chem-
ically synthesized sLea-KLH conjugate [224] revealed
that sLea-specific IgG and IgM antibodies were raised,
which showed no detectable cross-reactivity against a
series of other blood group-related antigens (e.g., Ley,
Lex, and sLex). Of note, some immunization studies
used structurally different constructs, in terms of both
TACA and carriers, indicating that the linker can sig-
nificantly affect the immunological response and thus,
have to be taken into account in vaccine design
[12,225–227].
Glycoconjugate vaccines containing mucin-like antigens:
the role of the immunogenic carrier and of multivalent
antigen display
Several glycoconjugate constructs containing struc-
turally different immunogenic carriers have been
designed with the aim to avoid cross-reactivity against
the carrier proteins. In particular, in the last 10 years
attention has been mainly focused on constructs con-
taining mucin-like antigens. Mucins (MUC) are the
most abundant macromolecules present in the mucus.
They are highly glycosylated proteins, synthesized
principally by epithelial cells, and they provide protec-
tion and lubrication to epithelial surfaces [228–230].
Although MUC1 is densely glycosylated in normal
cells, it is aberrantly glycosylated in cancer cells and
carries simple and truncated carbohydrates as a result
of alterations in glycosyltransferase expression, like
downregulation of the b1–6GlcNAc transferase or
aberrant expression of GalNAc transferases, or muta-
tions in the molecular chaperone COSMC [231–234].
Thus, immature O-glycan structures, such as Tn (Gal-
NAca-Ser/Thr) and TF (Galb1–3GalNAca-Ser/Thr,
Thomsen–Friedenreich) antigens, are expressed on
malignant cells and they are abundant TACAs
(Fig. 11). The aberrant overexpression and glycosyla-
tion of mucins drive oncogenesis, as they promote can-
cer cell differentiation, proliferation, invasion, and
metastasis [235,236]. The MUC1 extracellular domain
comprises of a variable number (30–200) of 20 amino
acid tandem repeats with the sequence SAPDTR-
PAPGSTAPPAHGVT [237]. Every repeat region
includes five potential O-glycosylation sites, three thre-
onine (Thr), and two serine (Ser) residues, the primary
attachment sites for the aGalNAc residue. In parallel,
a2–6- and a2–3-sialyltransferases are frequently upreg-
ulated, which causes premature sialylation of these
antigens, resulting in the formation of the sTn antigen
or the 2–3-sialyl-TF and 2–6-sialyl-TF determinants,
which are also considered TACAs (Fig. 11)
[189,208,238]. Additionally, incomplete glycosylation
in tumor cells leads to the exposure of peptide epi-
topes, which are masked in healthy cells. Moreover,
the expression level of MUC1 on tumor cells can be
100-times higher than that on normal cells, rendering
MUC1 glycopeptides an attractive target for cancer
immunotherapy [190,239,240].
With the aim to avoid the carrier protein and to
boost the immune response toward MUC antigens,
several approaches toward conjugates containing
TACA on structurally different carriers have been pro-
posed. BSA conjugates containing multiple copies of
sialylated and nonsialylated Tn and TF antigen linked
to the tandem repeat sequence of the PDTRP epitope
were able to evoke immunological memory, and both
the elicited IgG (mainly IgG1) and IgM antibodies
could recognize native antigens on breast cancer cells
[241]. The unimolecular pentavalent vaccine containing
MUC antigens together with the Globo-H and GM2
ganglioside (8; Fig. 12) was synthesized by conjugating
the glycan epitopes to a peptide scaffold, which was
subsequently linked to the KLH protein [222,242,243].
Preliminary immunization studies showed that the
multicomponent vaccine was able to elicit a strong
IgG/IgM response and that the antibodies cross-
reacted with the overexpressed carbohydrate antigens
on cell surface. This vaccine prototype has entered
Phase 1 clinical studies.
Seminal reports introduced the development of
TACA-based conjugates containing T-helper epitopes
[such as the Pan DR epitope (PADRe) and poliovirus
peptide] coupled to addressable functionalized tem-
plates [reversible addition fragmentation chain transfer
polymerization (RAFTs)], providing a multivalent dis-
play of TACA antigens and TLR ligands [244–247].
Notably, a two-component vaccine based on a TACA-
MUC1 glycopeptide and a T-cell epitope from TT
[248] was able to induce substantial titers of TACA-
specific antibodies. As a follow-up, the conjugation of
a TACA-MUC1 glycopeptide with the complete TT as
carrier protein (9; Fig. 12) was described. These conju-
gates induced high titers of tumor-associated MUC1-
specific IgG antibodies, which were able to discrimi-
nate between normal and tumor mammary cells. This
is one of the most potent MUC1 vaccine candidates
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and anti-TACA-MUC1 antibodies so far, allowing the
diagnosis of human pancreatic cancer [249].
The RAFT cyclopeptide scaffold has been further
exploited for the multivalent presentation of a cluster
of MUC1 antigen residues, containing two separate
spatial domains, which allow the presentation of both
the antigen and different immunogenic carriers [e.g., T
epitopes (both CD4+ and CD8+), TLR-ligands] on the
same construct [250–252]. Immunization studies in
mice have proven that these constructs are able to
induce both Th cells and CTL responses [252] and in
some cases established a reduction in tumor size in
mice inoculated with syngeneic murine cancer cells
[251]. Next, a cluster of Tn antigen, a Th epitope, a
CTL epitope, and a TLR2 ligand, combined in a gly-
coconjugate construct, could induce strong Ab
responses (10; Fig. 12) [253]. However, the immuno-
logical outcome, in terms of Ab titers and Ab speci-
ficity, was dependent on the spatial arrangement of the
T-cell epitopes within the construct [254].
In order to generate effective anti-MUC1 immune
responses, MUC1 peptides and glycopeptides have also
been conjugated by different research groups to VLPs,
such as the bacteriophage Qb, which could signifi-
cantly boost immune responses against glycopeptide
antigens [255]. The short synthetic Tn-nonapeptide of
MUC1 (SAPDT*RPAP, where * denotes glycosyla-
tion) conjugated to the bacteriophage Qb carrier was
even effective at inducing high levels of anti-MUC1
IgG antibodies in immune-tolerant human MUC1
transgenic mice. These antibodies exhibited high tumor
binding and killing activities, good selectivity in gly-
copeptide recognition, and excellent recognition of
human breast cancer over normal mammary tissues
[256]. Also the MUC1-TF and sTn glycopeptides (11;
Fig. 12) conjugated to Qb were used to immunize
human MUC1 transgenic mice. The MUC1-TF elicited
higher titers of anti-MUC1 IgG antibodies compared
with the Qb-MUC1-Tn conjugates. These antibodies
showed the strongest binding to MUC1-positive mela-
noma B16-MUC1 cells and effectively killed these cells
in vitro. Moreover, profylactic vaccination with Qb-
MUC1-TF could significantly reduce the number of
metastatic tumor foci in the lungs of immunized mice.
Many efforts have been dedicated to the synthesis
and evaluation of glycan-containing glycoconjugates
aimed at overcoming the T-cell-independent activation
of the immune system associated with TACA-based
epitopes. Significant contributions to this field have
come from the use of fully carbohydrate-based con-
structs composed of synthetic TACA-ZPSs conjugates
[257,258]. ZPSs are a unique group of microbial
polysaccharides expressed in some pathogenic strains
of S. aureus, S. pneumoniae type 1 polysaccharide, and
Bacteroides fragilis polysaccharide A1 and B, display-
ing strong immunogenic properties [259,260]. These
polysaccharides share a common feature of positively
and negatively charged centers within a single repeat-
ing unit, and they are therefore referred to as ZPS.
Some ZPSs have been reported to activate T cells
through entry into APCs utilizing the same endocytic
pathway as protein antigens, activating the MHC class
II-mediated CD4+ T-cell response [261–263] ZPSs,
including PS A1 and PS B from B. fragilis, have been
isolated from the capsule of the bacteria and struc-
turally modified for conjugation to TACA antigens
(e.g., Tn, sTn, TF, 12, and 13; Fig. 12) [36,257,258].
Adjuvant-free immunization protocols using Tn-PS A1
(12a; Fig. 12) in mice resulted in production of anti-
bodies able to recognize the Tn hapten on human
tumor cells, thus providing encouraging results for
anticancer immune responses [264], and indicating the
possibility of a dual role of PS A1 as both carrier and
adjuvant [257,258]. Indeed, PS A1 is known to bind
TLR-2 on DCs, which causes the release of IL-12. In
addition, PS A1 can enhance expression of CD40,
CD86, and CD80 on the surface of APCs [265,266].
These findings led to the discovery of a novel carbohy-
drate binding mAb, called Kt-IgM-8 [267]. This new
Ab, which was generated via hybridoma technique
from Tn-PS A1 hyperimmunized mice, was able to kill
sTn-expressing cancer cell line MCF-7 both in vitro
and in vivo [267]. Promising results have also been
obtained with TF antigen conjugated to PS B (13,
Fig. 12) [268], showing elevated IgM and IgG Ab
titers with anti-TF specificity after immunization in
mice. In a recent study, the sTn antigen was conju-
gated to PS A1 (sTn-PS A1, 12b; Fig. 12) and
combined with a commercially available monophos-
phorylated derivative of lipid A (MPLA) for immu-
nization studies in mice, where it elicited a strong
immune response with the generation of anti-sTn
IgM/IgG antibodies. These antibodies were able to
bind sTn-expressing cancer cell lines MCF-7 and
OVCAR-5 [257]. Recently, a tetrasaccharide repeating
unit of PS A1 was synthesized with alternative charges
on adjacent monosaccharides with the aim to dissect
the role of ZPSs in carbohydrate immunity [269].
Glycomimetics in the discovery of anticancer
glycoconjugate vaccines
The main drawback of therapeutic vaccines is that
cancer cells readily adopt immune escape mechanisms
[270], resulting in increased resistance to immune
recognition. An attractive approach to tackle these
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issues may be the use of unnatural derivatives, like
TACA analogs and/or glycomimetics [8,36]. In princi-
ple, these derivatives would be more resistant to enzy-
matic degradation, which could translate into stronger
and longer-lasting immunogenicity and protective effi-
cacy [84]. The substitution of a hydrogen with a fluo-
rine atom on TACAs (e.g., sTn, Globo-H) has been
successfully investigated by some other research groups
as well [226,271]. The comparable size of fluorine atom
compared with hydrogen is probably the reason why
the antibodies elicited in immunization protocols are
still able to recognize the natural antigen. For exam-
ple, a vaccine carrying a fluorinated TF antigen was
able to elicit strong responses in mice and the resulting
antibodies showed a similar structural selectivity to
those obtained with the natural vaccine [84,272]. A tri-
partite vaccine containing the more immunogenic
domain of MUC1 and the unnatural amino acid a-
methylserine glycosylated with GalNAc (glycopeptide
14; Fig. 13) was more resistant to enzymatic degrada-
tion than the natural counterpart and elicited an
immune response comparable to a vaccine candidate
containing a natural MUC1 fragment [273]. There-
after, a new strategy for designing potent antigen mim-
ics was proposed based on the replacement of the
anomeric oxygen with a sulfur or a selenium atom
[274]. These minimal chemical modifications bring
about two key structural changes to the glycopeptide.
Namely, they increase the carbohydrate-peptide dis-
tance and change the orientation and dynamics of the
glycosidic linkage. As a result, the peptide acquires a
preorganized and optimal structure suitable for Ab
binding. Indeed, these synthetic glycopeptides could
adopt a distinct structure in solution, which markedly
differs from their natural counterparts. Compared to
the native antigens, these new glycopeptides displayed
an improved binding to a representative anti-MUC1
Ab. To prove the potential of these glycopeptides as
tumor-associated MUC1 antigen mimics, the derivative
bearing the S-glycosidic linkage was conjugated to
AuNPs and tested in mice in a formulation without
adjuvant. As a result, significant humoral immune
responses were induced and, in particular, the murine
antisera recognized cancer cells in biopsies of breast
cancer patients with high selectivity. These findings
demonstrate that the antibodies elicited against the
mimetic antigen were able to recognize the naturally
occurring glycosylated antigen in its physiological con-
text. In this framework, a hydrolytically stable mimetic
of a GM3 metabolite expressed on melanoma cells
(e.g., GM3-lactone) [275] has been recently proposed.
Even if structurally simpler than the endogenous anti-
gen, it maintains the characteristic folded shape of the
native GM3-lactone. This mimetic was conjugated to
structurally different scaffolds ranging from protein
(e.g., KLH) [275], to multivalent scaffolds [e.g., cal-
ixarene, carbon-based nanomaterials, and an address-
able functionalized templates (RAFTs)] [276,277].
The ability to induce a specific immune response
and to affect melanoma progression was evaluated
both in in vitro and in vivo studies. In particular, the
KLH conjugate 15 (Fig. 13) was successfully elicited
Ab titers with confirmed specificity for GM3. In addi-
tion, a conformationally constrained mimetic of the
Tn antigen was developed into a fully synthetic vaccine
prototype, consisting of four copies of the antigen
mimetic and an immunogenic PADRe peptide dis-
played on the two sides of a RAFT template. This
vaccine prototype has been used in immunization stud-
ies in mice and elicited long-lasting antibodies (e.g.,
IgG1, IgG2a, and IgG3) able to bind Tn expressing
MCF-7 human breast cancer cells [278]. The same
Fig. 13. Structures of: 14 a tripartite
vaccine containing the unnatural amino acid
a-methylserine glycosylated with GalNAc;
[273] 15 GM3-lactone mimetic conjugated
to KLH protein [275].
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mimetic was also able to activate iNKT cells, when
conjugated to a phospholipid carrier, which enabled
the mimetic to be presented in the context of the con-
served nonpolymorphic MHC class I-like molecules
(CD1d) [279]. Modification at the N-acetamido posi-
tion of the galactose residue of MUC antigens and in
the sialic acid containing antigens (e.g., GM3, sTn,
sTF) has likewise been widely investigated [280–283].
In this context, a study on Tn and sTn analogs con-
taining either a thio-glycosidic linkage and modifica-
tions at N-acetamido group of both galactose and
sialic acid residues have been recently reported [284].
Some of these analogs have been conjugated to carrier
proteins and stimulated IgG antibodies responses,
which were able to recognize the natural antigens in
ELISA.
Nanoglycoconjugates
Nanotechnology approaches have been proposed to
improve the delivery of anticancer drugs by reducing
side effects and improving therapeutic efficacy [285].
Much effort has been dedicated to find the optimal
nanosystem, through combinations with microparticles
and via multistage vector approaches, aimed at target-
ing the tumor microenvironment and overcoming the
biological barriers, which can reduce the therapeutic
efficacy [286]. Functionalized NPs for anticancer drug
delivery are a major strategy, which depends on the
proper selection of the target (glycoconjugate and
cancer-associated glycoform). This specificity depends
on the tumor type, and therefore, successful targeting
requires a detailed analytical tumor glycophenotype
characterization. Regarding cancer immunotherapies,
NPs have been used for delivery of immunomodula-
tory compounds in combination with chemo- or radio-
therapy, and as platforms for antigens and adjuvants
codelivery in order to generate therapeutic T cells
[287,288]. Due to the key role of glycans in cancer sig-
naling and development, the combination of NPs and
carbohydrates is showing promise for prolonged
immune stimulation and modulation toward novel
carbohydrate-based nanovaccines [289].
Diverse nanocarriers in terms of structure, shape,
chemical composition, properties, and degree and type
of functionalization have been proposed for the multi-
valent antigen display of vaccine prototypes. In addi-
tion, nanotechnology allows for multifunctional
theranostic systems to be designed [289]. As it was
already discussed in section Improving the immuno-
genicity of pathogen glycan structures through glyco-
conjugate vaccines, liposomes are very attractive
nanocarriers since they are versatile, biocompatible
and characterized by a low immunogenicity and toxic-
ity, and they offer the opportunity to carry multicopy
of different ligands mixes [290,291]. Liposomes con-
taining fully synthetic anticancer vaccine candidates
able to generate T-cell-dependent Ab response in mice
have been reported in a seminal study by Boons et al.
[292]. They studied the effect of self-adjuvating and
multicomponent vaccines combining the Tn antigen or
a partial sequence of the TACA-MUC1 tandem repeat
including the Tn antigen in the PDTR region, a TLR2
ligand (e.g., Pam3CysSerK4), and T-cell peptide epi-
topes, for the activation of the adaptive immune sys-
tem [12,190]. Strong IgG responses were elicited in
wild-type mice, and further mechanistic studies in a
mouse model of mammary cancer demonstrated that
the elicited IgGs were able to neutralize cancer cells by
Ab-dependent cell-mediated cytotoxicity, that is, acti-
vation of cytotoxic T-lymphocytes [293]. Varying these
lipidated glycopeptides by proper modulation of the
MUC1 glycosylation and peptide length, the inclusion
(and the type) of endogenous T-helper epitopes [294],
or the structure of TLR2 ligand (e.g., Pam3CysSerK4
vs Pam2CysSerK4) [295] should help at finding the
optimal formulation toward therapeutic antitumor
glyco-nano-vaccines. Notably, in all these studies the
presence of the TACA and the covalent conjugation of
the vaccine components were essential to reach a speci-
fic immune response [293,296]. More recently, a lipo-
some formulation containing the tandem repeating
unit of MUC-1 conjugated to the TLR2 ligand (16;
Fig. 14) has been reported. Immunization studies
showed that even without exogenous helper T epi-
topes, the vaccine candidate was able to activate T
cells and to elicit robust cytotoxic IgG Ab responses
[294].
Also CpG motifs have been employed as built-in
adjuvant [297]. The immune response of a tripartite
vaccine candidate, composed of a Tn glycosylated
MUC1 epitope, a CpG-ODN, and a T-helper epitope,
was investigated in a mouse model of breast cancer,
and compared to the responses elicited by a similar
compound with the lipopeptide Pam3CSK4 as a built-
in adjuvant. A weaker cellular immune response was
reached with the CpG-ODN-containing vaccine candi-
date compared with the Pam3CSK4 conjugate. More-
over, the CPG tripartite vaccine could not significantly
reduce the tumor burden over control in a mouse
model, demonstrating that the nature of the covalently
linked adjuvant significantly impacts the quality of the
immune response. Although the conjugation of a pro-
tein antigen to CpG-ODN creates a potent immuno-
gen with therapeutic implications [298,299], more
studies are needed for the optimization of a vaccine
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Fig. 14. Structures of: 16 glycoconjugate vaccine containing tandem repeating unit of MUC-1 conjugated to the TLR2 ligand [294]; 17
glycoconjugate vaccine containing a TACA antigen (sTn, GM3, Globo-H) conjugated to a TLR-4 ligand [300–302], 18 a synthetic Tn antigen-
glycolipid containing an a-GalCer residue [305]; 19 Au nanoconstructs, containing the TF disaccharide antigen instead of the Tn antigen.
Figure of compound 19 reproduced from Ref. [308]. Copyright 2012, American Chemical Society.
33The FEBS Journal (2021) ª 2021 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
M. Anderluh et al. Glycoconjugate vaccines in infections and cancer
containing antigenic saccharides or glycopeptides con-
jugated to a TLR-9 ligand.
The targeting of TLR receptor has also been investi-
gated using a fully synthetic vaccines based on a car-
bohydrate antigen (sTn, GM3, Globo-H) and MPLA
residue conjugated through a linker (17; Fig. 14) [300–
302]. Indeed, as discussed in section Bacterial infec-
tions, MPLA works as a TLR-4 agonist on the APC
surface and it is well-known for its strong immunos-
timulatory activity. GM3 conjugated to MPLA 17
(Fig. 14) was incorporated into liposomes and subse-
quently inoculated in mice [300]. The resulting con-
structs elicited T-cell-mediated immunity without an
external adjuvant, thus showing self-adjuvating proper-
ties. The generated antibodies were able to bind to tar-
get tumor cells. Surprisingly, the immunological
activity of the conjugates was reduced rather than
increased, when inoculated together with an external
adjuvant, for example, Titermax Gold. Moreover, the
liposome formulation seems to be crucial for the
immunological activity. Indeed, immunization of mice
using pure glycoconjugates yielded inconsistent results,
which was ascribed to glycoconjugate insolubility in
buffer and a lack of a homogeneous preparation [300].
In this context, four monophosphoryl derivatives of
N. meningitidis lipid A conjugated to sTn antigen [301]
and formulated as liposomes elicited high titers of
antigen-specific IgG antibodies, in adjuvant-free condi-
tions. Among the MPLAs examined, the natural
N. meningitidis MPLA exhibited the most promising
immunological activity. Promising results toward the
development of anticancer vaccines were also obtained
with MPLA conjugated to the GM2 TACA, a tumor
antigen overexpressed in several tumor types, such as
renal cancer, sarcoma, and melanoma [303].
The same strategy was applied for the synthesis of
self-adjuvating Globo-H-MPLA glycoconjugates 17
(Fig. 14) [302]. Formulated as liposomes, these Globo-
H-glycoconjugates were shown to elicit high production
of IgG1 Ab and activation of T-cell-dependent immu-
nity. The antibodies induced by this vaccine prototype
had the ability to bind to Globo-H-expressing MCF-7
cancer cells and to mediate strong complement-
dependent cytotoxicity.
The immunostimulatory potential of LPS lipid A is
strongly influenced, and tuned by its primary structure,
and thus, the moderate agonist activity of LPS isolated
from nonhuman pathogenic bacteria can also be
exploited to design potential cancer vaccine adjuvants.
With the aim of improving anticancer vaccination pro-
tocols, a micellar-based platform was developed for
improved codelivery of a LPS lipid A, acting as a
moderate TLR4 agonist, and a model antigen. This
pathogen-mimicking nanovaccine featured the model
antigen OVA linked to iron oxide NPs to which the
adjuvant, namely LPS from the plant-pathogen Xan-
thomonas campestris (Xcc LOS), was grafted. The
nanovaccines were able to elicit antitumor immune
responses against B16-F10 melanoma, whereby its
delivery as iron oxide NPs improved the immunostim-
ulatory properties and promoted reduced cytotoxicity
[304]. Recently, size-controlled glyco-liposomes were
prepared by employing a synthetic Tn antigen-
glycolipid containing an a-GalCer residue (18, Fig. 14)
[305]. In this construct, the a-GalCer glycosphingolipid
acts as an immunostimulatory agent for the weakly
immunogenic Tn antigen [136]. The resulting glycan
liposomes were used to immunize mice and were able
to generate specific high-affinity antibodies and T-cell-
dependent immunity, without the use of further adju-
vants. Moreover, the use of liposomes with tunable
sizes demonstrated that it is possible to drive the
response toward cellular (Th1) or humoral (Th2)
immunity when larger (around 400 nm) or smaller
(around 120 nm) NPs are employed, respectively.
Next to liposomes, other nano-prototypes have been
evaluated as potential anticancer vaccines. A
supramolecular self-assembling peptide of Nap-
GDFDFDYDK (where the upper D denotes amino acid
of the D-series) has been reported as an efficient
nanovector, which worked both as a multivalent car-
rier and as an adjuvant. In particular, the Tn-Nap vac-
cine self-assembled into NPs and elicited a potent
immune response (both humoral and cellular). More-
over, the antisera induced by Tn-Nap mediated a
strong complement-dependent cytotoxicity (CDC) to
breast cancer MCF-7 cells [306]. Immunization studies
with AuNPs tailored with a MUC1-derived glycopep-
tide, containing three Tn antigens per peptide, and the
T-cell epitope P30 from TT indicated Th1 and Th2
mediated immune responses directed to the glycopep-
tide antigen [307]. On gold nanoconstructs, containing
the TF disaccharide antigen instead of the Tn antigen
(19; Fig. 14) [308], the B-cell and T-cell epitopes were
separately conjugated onto the nanoplatform. Mice
were immunized with AuNPs bearing one or two TF
antigens accommodated on a MUC4-related peptide
and a peptide from the complement-derived protein
C3d (for B-cell activation). Analysis of antisera
revealed statistically significant IgG and IgM
responses, which strongly depended on the number
and position of the TF substitution in the glycopep-
tides and were mainly directed toward the glycopep-
tides and, only in part, toward the free peptide and
the linker. A combination of AuNPs with glycopoly-
mers has been reported by B. G. Davis and
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collaborators as a potential synthetic and multivalent
Tn-based cancer vaccine [46]. Homopolymers bearing
multiple copies of the tumor-associated Tn antigen,
conjugated to AuNPs, elicited a quite Tn-specific
immune response in rabbits, whereby a glycan density
of 20–25 units per polymer chain appeared optimal.
The density of Tn antigen presumably influenced the
B-cell response through cross-linking of B-cell recep-
tors and coreceptors, which in turn modulated B-cell
activation and IgG production. Although the absolute
IgG titers were lower than those obtained with related
glycoconjugate vaccines, the absence of carrier proteins
or immunogenic peptides seems to indicate the possi-
bility that a high multivalent display of the carbohy-
drate antigens is able to compensate for the lack of
other immunogenic components [304]. In addition to
the need of multivalent TACA display, synthetic
strategies have been developed to improve their in vivo
stability/availability. In particular, a structurally con-
strained mimetic of Tn antigen, resistant to enzyme-
mediated degradation, was multimerized onto iron
oxide NPs, which also can be combined with tumor
treatment (magnetic hyperthermia, in addition to vac-
cination), diagnosis, and monitoring (contrast agents
for magnetic resonance imaging) [309]. The conjuga-
tion of the same synthetic Tn antigen mimetic to bio-
compatible and water-dispersible dextran-based single-
chain NPs afforded nanosystems capable of specifically
activating the innate immune system through the mul-
tivalent presentation of the carbohydrate antigen [310].
Although not tested in vivo, these NP-based systems
are promising, as the Tn antigen mimetic already
showed immunogenicity in mice [278].
Final remarks and future perspectives
When designing TACA-based anticancer vaccines, one
must consider that cancer cells exploit the immune
modulatory ability of mucins to evade immune surveil-
lance. Mucin-associated (sialyl-)Tn antigens bind to
various receptors present on the DCs, macrophages,
and natural killer (NK) cells, resulting in overall
immunosuppression either by receptor masking or by
inhibition of cytolytic activity [311–313]. The Tn anti-
gen is famous in this respect through its specific bind-
ing to the CLR MGL (macrophage galactose-type
lectin). Upon binding of the Tn antigen by the MGL
receptor, which is abundantly expressed on tolerogenic
DCs and macrophages [314], the DC secretes large
amounts of the anti-inflammatory cytokine IL-10 [315]
and is also able to instruct the differentiation of regu-
latory Tr1 cells [316]. A recent report even indicates
that binding of tumor-associated glycans to MGL
leads to metabolically quiescent DCs [317], which
could strongly hamper vaccine efficacy when combined
with IL-10 secretion and Tr1 induction. Therefore,
caution is needed when using tumor-associated glycans
in vaccine preparations, and also the potential
immunosuppressive properties of the vaccine should be
carefully addressed.
Spike protein glycosylation of SARS-
CoV-2 and glycan-mediated
interactions
Betacoronaviruses, and among them SARS-CoV-2,
express on their surface glycosylated spike proteins
[318]. To date, there is no evidence available, support-
ing the possibility to exploit the spike protein glycan for
the development of glycoconjugate vaccines (where the
antigen is a pathogen-associated glycans),toward SARS-
CoV-2. Nevertheless, some recent papers have described
that the degree of glycosylation on the spike protein
plays a crucial role in the molecular recognition pro-
cesses by lectins expressed on immune cells and there-
fore in the mechanisms of the SARS-CoV-2 uptake and
infection. In particular, the spike protein from SARS-
CoV-2 participates in different carbohydrate-mediated
interactions at the host-pathogen interface. The SARS-
CoV-2 spike glycoprotein expressed in human embry-
onic kidney 293 cells (HEK293) displays different glyco-
sylation sites decorated with a combination of high
mannoses and complex-type oligosaccharides, including
highly processed sialylated complex-type and fucosy-
lated N-glycans [319,320]. In addition to the mentioned
N-glycan profile, O-linked residues have been also
described [320]. 3D structures of the spike glycoprotein
from SARS-CoV-2 have been recently reported based
on reported 3D structures and glycomics data for the
protein produced in HEK293 cells (Fig. 15) [321]. These
3D structures revealed that, similarly to the HIV gp120,
the glycans on the spike protein of SARS-CoV-2 shield
approximately 40% of the protein surface, with the
notable exception of the ACE-2 binding site [321].
The glycan shield on the SARS-CoV-2 spike protein
could have several immunologic implications important
to control and understand the COVID-19 pandemic
[322]. In this context, the SARS-CoV-2 spike protein
showed binding to different human lectins in solid-
phase immunoassays (i.e., SPR and STD-NMR experi-
ment) [323,324]. The C-type lectins DC-specific intercel-
lular adhesion molecule-3-grabbing nonintegrin and
MGL, as well as sialic acid-binding immunoglobulin-
type lectin 9 and 10, recognized the SARS-CoV-2 spike
protein in most of these assays. Functional in vitro
experiments also proved and confirmed the roles of
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different human lectins in “supporting” the viral infec-
tion [323]. Conversely, the spike protein can recognize
structures and glycans from the host, especially during
the first infection steps. The SARS-CoV-2 primarily
binds to angiotensin-converting enzyme 2 (ACE2), but
different glycosylated host-structures can be accommo-
dated as other viral attachment points. Heparan sulfates
have been reported to bind SARS-CoV-2 [325,326] as
well as heparin [327]. Interestingly, the SARS-CoV-2
spike protein could also be involved in different
carbohydrate-mediated interactions with the host lung
microbiota glycoconjugates. As recently described with
solid-phase immunoassays, the spike protein was able
to specifically bind to some CPS of S. pneumoniae as
well as to the LPS from P. aeruginosa [324].
Interestingly, the SARS-CoV-2 glycosylation sites are
highly stable and do not differ between 7813 isolates
tested [328], suggesting that the glycosylation of SARS-
CoV-2 might be crucial for innate immune evasion.
Understanding and interfering with these immune inter-
actions could help in designing novel therapies and sup-
porting from a different angle the complex clinical
aspects of the COVID-19 pandemic. In addition, taken
together these preliminary data suggest the importance
of carbohydrate-mediated interactions during the
SARS-CoV-2 infection [321]. This could help in design-
ing glycan-based therapies or to have better clinical per-
spectives for patients’ diagnosis and prognosis.
Final considerations and future
perspective
Since the early days of Edward Jenner, vaccine develop-
ment has experienced a tremendous evolution, leading
to the successful eradication of smallpox and the near
control of other infectious diseases, such as polio or
mumps. However, effective vaccines for rapidly evolving
pathogens, such as the HIV, have not yet been estab-
lished. Moreover, the recent COVID-19 pandemic has
emphasized that novel viruses could manifest at any
time and that vaccine development will be a continuous
process to contain these emerging novel pathogens.
The use of carbohydrates in vaccine design has not
reached its full potential, considering that the unique
glycan coats, covering both pathogens and tumor cells,
provide attractive, novel vaccine candidates. Through
the coupling to immunogenic carriers, such as
immunogenic proteins, lipids, nuclei acids, or incorpo-
ration into NPs of liposomes, humoral responses can
be induced to bacterial polysaccharides, viral spike
proteins, or tumor-associated glycan antigens.
Nevertheless, several challenges in carbohydrate vac-
cine development lie ahead. So far, many efforts have
focussed on identifying appropriate carriers and adju-
vants in order to elicit the appropriate immune reac-
tions. Although many small advances have been made,
the treatment of cancer and HIV through vaccination
still requires breakthrough innovations. In parallel to
continued attempts to identify the most optimal carrier
and adjuvant pairs, one may utilize, as vaccines, glyco-
variant cell lines that are known to induce specific
anticarbohydrate IgG antibodies. As crucial differences
exist between the human and murine glycosylation pat-
terns as well as in their respective immune systems,
observations made in mouse experiments may not be
directly translated into humans. Phase I, II, and II
clinical trials may take a long time, and most vaccine
candidates identified in mice may thus fail.
One additional challenge might be the resistance
developed by pathogens and cancer cells due to the
Fig. 15. 3D models of the glycosylated S
(spike) protein of SARS-CoV-2. High-
mannose structures Man9 are depicted in
green and Man5 in dark yellow. Hybrid N-
glycans are shown in orange and complex
N-glycans in pink. Figure reproduced from
Ref. [321].
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suppression of carbohydrate antigen expression. This
acquisition of resistance could easily nullify the effects
of vaccination. Unfortunately, this could be easily
achieved by shutting down the expression of certain
glycosyltransferase gene(s) by DNA methylation and/
or histone modification, and/or by expressing certain
glycosyltransferase gene(s) followed by the modifica-
tion into another structure, and/or by expression of
certain glycosidases.
Moreover, the expression of many glycans, though
cell type dependent, may be shared among different
cells. Therefore, there is always a possibility of causing
unfavorable side effects, including autoimmunity,
through the use of carbohydrate-based vaccines. Due
to molecular mimicry between bacterial, tumor and
human peptides and oligosaccharides, auto-antibodies
may be generated, which are responsible for inflamma-
tory reactions resulting in development or progression
of autoimmune diseases. In this regard, we should not
forget about the human microbiome present in intes-
tine, skin, and urinary tract, where it contributes to
health as well as disease development. Thus, potential
vaccines need to consider bacterial cell glycan surface
based molecular mimicry.
We envision that a continuous crosstalk between
chemists and immunologists will substantially pro-
gress the field. This review could provide a road-
map and starting point to initiate novel
collaborative efforts to advance our knowledge on
antiglycan immune response and the development
of the next generation of carbohydrate-based vacci-
nes.
Box 1. Bringing vaccines from the lab onto the market
Most of the contemporary vaccines in the final drug product formulation contain either single or multiple sets of
antigens and adjuvant(s). According to the definition accepted by regulatory agencies worldwide, the drug product is
a finished dosage form (e.g., tablet, capsule, or solution) that contains one or more drug substances (i.e. antigens,
pure materials, which exert a pharmacological action), in combination with excipients and adjuvants meant for use
by humans.
Vaccine antigens and vaccine product presentations vary in complexity, from single or multivalent antigens (recombi-
nant protein, live attenuated, bioconjugates, etc.) to encapsulated nucleic acids encoding the antigen of interest. These
antigens are intended to elicit the appropriate immune response and ultimately protection in vaccinated individuals.
To assure vaccine safety and efficacy, each of the components has to be stable during manufacturing, storage, and
administration. As such, it is important to understand molecular properties and degradation pathways of the antigen
or various antigens that will make up an intended vaccine product.
The stabilization of the multicomponent vaccine encompasses challenges of characterization and stabilization of each
antigen in the mixture. In addition, interactions of the antigen with adjuvant and the stability of the adjuvant (e.g.,
the instability of aluminum adjuvants during freezing, often resulting in irreversible aggregation/agglomeration that
can lead to low reproducibility of otherwise efficacious vaccine) have to be evaluated.
Preformulation development is focused on probing these molecular susceptibilities and understanding potential degra-
dation pathways through stress testing of the antigens and proper analytical characterization. Preformulation will aid
in indicating the likely path for formulation development, either liquid formulation or solid-state formulation
(lyophilization). During formulation development, excipients (buffer, sugars, surfactants, antioxidants, etc.) and con-
centrations of excipients are selected based on ability to infer stability on the antigen(s) and based upon function for
intended dosage form.
All characteristics of formulation will also impact processability and must be carefully selected to ensure a manufac-
turable product with adequate shelf-life. During the development life cycle for drug products from early clinical entry
to late-stage activities, adjuvant considerations, interactions, and impact on final administration must also be consid-
ered in formulation design.
Once a preclinical proof of concept has been established for a new vaccine formulation candidate, the clinical devel-
opment is typically carried out in well-defined stages (i.e., Phases I, II, and III; Fig. 16 (Box 1)), with increasing num-
bers of study participants at each stage, to minimize potential adverse impacts of the vaccine candidate on study
subjects, as well as to determine whether clinical effects warrant proceeding to more comprehensive efficacy studies,
involving much larger numbers of study subjects. The use of materials that are comparable to those that first
achieved the proof of concept for the vaccine candidate is a fundamental requirement starting from the toxicology
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